US3622677A - Compressed tablets containing compacted starch as binder-disintegrant ingredient - Google Patents

Compressed tablets containing compacted starch as binder-disintegrant ingredient Download PDF

Info

Publication number
US3622677A
US3622677A US839590A US3622677DA US3622677A US 3622677 A US3622677 A US 3622677A US 839590 A US839590 A US 839590A US 3622677D A US3622677D A US 3622677DA US 3622677 A US3622677 A US 3622677A
Authority
US
United States
Prior art keywords
starch
compacted
binder
tablets
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US839590A
Inventor
Rolland W P Short
Frank Verbanac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Staley Continental Inc
Primary Products Ingredients Americas LLC
Original Assignee
Tate and Lyle Ingredients Americas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tate and Lyle Ingredients Americas LLC filed Critical Tate and Lyle Ingredients Americas LLC
Application granted granted Critical
Publication of US3622677A publication Critical patent/US3622677A/en
Assigned to STALEY CONTINENTAL, INC., ROLLING MEADOWS, ILLINOIS, A DE CORP. reassignment STALEY CONTINENTAL, INC., ROLLING MEADOWS, ILLINOIS, A DE CORP. ASSIGNMENT OF ASSIGNORS INTEREST. EFFECTIVE DEC. 30, 1987. Assignors: A.E. STALEY MANUFACTURING COMPANY, A DE CORP.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • This invention relates to the manufacture of compressed tablets and more particularly to compressed tablets which contain a starch binder-disintegrant ingredient in the form of a directly compressible compacted starch powder which permi the tablets to be made by the direct compression technique.
  • the compressed tablet form is, by far, that most frequently employed today. Ease of packaging and handling, and, most important accuracy of dosage in administration are among the advantages stemming from the use of medicament-containing tablets. For essentially the same reasons, the compressed tablet also plays an important role in other fields as a dispensing unit. Examples of nonpharmaceutical materials marketed in compressed tablet form include such diverse materials as laundry detergents, confections, artificial sweeteners, fish foods, plant growth regulators, pesticides, herbicides, and dyes. While the actual characteristics of various tablets differ depending on the particular nature and planned use of the several tablets, the generally more important characteristics fall into three areas of consideration.
  • an evaluation of the tablet includes a consideration of the tablet disin tegration properties in the fluid medium. While some tablets such as those designed for use as a throat lozenge desirably are slowly disintegrative in the fluid medium in which they are placed for use, in most cases rapid disintegration of the tablet is desired.
  • a tablet embodying an ingestible analgesic, such as aspirin should rapidly break down in the digestive fluid of the stomach to make the active ingredient promptly available to the organism.
  • the present invention is particularly concerned with such tablets of relatively rapid disintegration capability.
  • the second and third important tablet characteristics, friability and hardness, are somewhat related in that as tablet hardness increases the friability of the tablet generally decreases. Excessive friability is undesirable since dusting and crumbling of the tablet results in at least some diminution in active ingredient dosage, detracts from the tablet appearance and consumer appeal, and reduces the effectiveness of any tablet markings. insufficiently hard tablets, in addition to exhibiting the efl'ects of excessive friability, are prone to breakage and chipping, particularly in transport where they may be subjected to repeated mechanical shock.
  • a hard, nonfriable tablet possessing acceptable disintegration characteristics is the goal of the tablet manufacturer.
  • Other properties are, of course, important such as color stability and nonhygroscopicity but the desideratum remains the production of a tablet of the type described.
  • Certain materials such as sodium chloride, paradichlorobenzene, hexamethylenetetramine, and certain medicaments are readily directly compressed alone in dry form into a firm, coherent mass in a tablet machine.
  • the tabletted formulations generally also contain additional ingredients, such as lubricants, disintegrants, fillers, colorants, and the like.
  • binding agent binder
  • filler are self-explanatory.
  • a disintegrant is an agent which is effective, when the tablet is placed in the proper fluid environment, to promote destruction of the tablet's physical integrity.
  • a typical disintegrant employed in tabletting is granular starch.
  • a given material may perform more than one of the single functions of binding, filling, and promoting disintegration.
  • the principal component, other than the active ingredient, that is employed to provide the improved compressed tablets of the present invention is such a dual-functioning material and is referred to herein as a binder-disintegrant.
  • the wet granulation technique involves adding a moistening agent such as water or ethylene glycol to the tabletting in gredient mixture to prepare a moistened mass, oven drying the wetted mass, and milling the dried mass into granules adapted to be used in the tabletting machine.
  • a moistening agent such as water or ethylene glycol
  • the wet granulation method likewise is undesirably time consuming and expensive. This method, moreover, has the limitation of not being useful when the tablet ingredients are incompatible to wetting or are heat sensitive.
  • the third and simplest procedure employed in preparing tabletting formulations involves intimately and uniformly dry blending the ingredients employed, e.g. active ingredient, binder, filler, disintegrant, and lubricants, to provide a pulverulent mixture displaying the requisite flowability for adequate feeding to the tablet machine. Since in this method the granulation step is eliminated, the formulations are said to be directly compressible" into tablets, and the tablet-forming operation is referred to as direct-compression" tabletting. This procedure, by virtue of its simplicity, obviously is preferred for use. Using ingredients heretofore available, however, the ingredient mixtures obtained by mere dry mixing generally do not exhibit adequate flowability and are not adapted to be fed directly to the tabletting machine to prepare tablets of uniform and acceptable properties.
  • ingredients employed e.g. active ingredient, binder, filler, disintegrant, and lubricants
  • FIG. 1 is a photomicrograph, taken under bright field illumination of ordinary corn starch at a magnification of 425;
  • FIG. 2 is a photomicrograph corresponding to FIG. 1 but with the light polarized
  • 3 is a photomicrograph, taken under bright field illumination of compacted corn starch, useful in accordance with the present invention, at a magnification of 425;
  • FIG. 4 is a photomicrograph corresponding to FIG. 3 but with the light polarized.
  • Compacted starches constitute a known class of materials. They are prepared by subjecting a granular starch raw material to pressure in the presence of water to effect distortion and fracture of at least some of the granules and produce adhesion between particles of the resultant mass.
  • the resultant compacted material may have differing cold-water swelling properties and contain varying amounts of cold-water soluble material depending primarily upon the particular pressure, temperature, and moisture conditions utilized. Specific techniques commonly employed include passing the starting starch through the nip of rotating rolls operating at the same or different speeds, as described in US. Pat. Nos. 2,098,293; 2,168,524; 2,464,081; and 3,196,044, and working the starch in the course of an extrusion operation as shown in US. Pat. Nos.
  • Compacted starches heretofore have found utility primarily as dustless carbohydrate nutrients in the brewing industry and as binders in the preparation of rough-molded products containing relatively coarse aggregate materials such as foundry cores and charcoal briquettes.
  • compacted starch powers advantageously are characterized by properties which enable them to be dry mixed with active ingredients and conventional tabletting aids, such as fillers, lubricants, and the like, to prepare active ingredient-containing formulations which are directly compressible into tablets in conventional tabletting equipment.
  • the present invention therefore provides a highly valuable means whereby tabletting operations may be greatly simplified, and the troublesome and time-consuming preliminary granulation and slugging steps which characterized most tabletting operations heretofore available may be eliminated.
  • the compacted starch powders employed in the present invention advantageously are characterized by properties which satisfy both the requirements of a binder for the active ingredient and a disintegrant for the tablet in aqueous media.
  • suitable direct compression tablets of satisfactory hardness, friability, and disintegration properties advantageously may be prepared by means of the present invention using the compacted starch powders as a sole, dualfunctioning binder-disintegrant, and the heretofore commonly required practice of adding separate ingredients as the binder and disintegrant with the attendant problems of properly mixing multiple ingredients and balancing dosage levels no longer need be followed.
  • the starch binder-disintegrant ingredient employed in preparing direct compression tabets in accordance with the present invention furthermore, easily and cheaply may be obtained from readily available and inexpensive starting raw materials, namely granular starches.
  • binder-disintegrant compacted starches many embodiments are characterized by low color, color stability, and acceptability for human consumption.
  • the present invention therefore, includes what may be said to be a universal" ingredient for direct compression tabletting, whereby a wide range of active ingredients, including many pharmaceuticals tabletted heretofore only with great difficulty, if at all, now easily and inexpensively may besatisfactorily tabletted by direct compression.
  • the compacted starch powders employed in the practice of the present invention are derived from appropriately compacted granular starch raw materials and are superficially dry, free flowing, partially cold-water soluble materials which swell in cold water and have a relatively high loose bulk density.
  • the powders themselves are directly compressible in conventional tabletting equipment into relatively rapidly disintegrative placebo tablets of high hardness and low friability.
  • Microscopic examination of the compacted starch powders reveals the starch content of the materials to be in the form of a mixture of birefringent granules and nonbirefringent fragments of granules, in which some aggregates of granules and fragments are present.
  • FIGS. 1-4 These characteristics of the compacted starch powders on microscopic examination are apparent from the photomicrographs reproduced in FIGS. 1-4.
  • FIG. 1 granules of ordinary corn starch are shown as viewed with unpolarized light at 425 magnification.
  • FIG. 2 shows the same granules viewed with the light polarized at the same magnification. It will be noted that in FIG. 2 the granules all exhibit birefringence (i.e. the crosses) which is characteristic of starch granules.
  • FIG. 3 a sample of compacted starch powder, which is directly compressible into tablets in accordance with this invention, is shown as viewed with unpolarized light at 425 magnification. A number of starch granules appear in F IGv 3 along with aggregates and granular fragments.
  • the sample is a mixture of birefringent granules and nonbirefringent fragments of granules, in which there are aggregates of granules and fragments.
  • a placebo tablet is a tablet prepared by directly compressing one material alone such as a compacted starch powder.
  • cold-water solubility, swelling power, hardness,” friability,” disintegration time, and granular starch raw material are defined as follows:
  • the weight of the dried material in the pan multiplied by 400 and divided by the dry substance weight of the original sample is the cold-water solubility of the starch material.
  • commonly available granular starches are essentially cold-water insoluble, generally containing less than about 2 percent by weight cold-water solubles and in the case of unmodified starches less than about 1 percent.
  • Hardness a measure of the strength of tablets (average of or more tablets) and their ability to retain their physical integrity, expressed in terms of kilograms, as determined by the conventional procedure using a model B tablet hardness tester of the Strong-Cobb-Amer Company, Cleveland, Ohio, to obtain an indicated pressure gauge reading at fracture of the tablet (tablet mounted on edge in tester) and multiplying the indiczwu hardness value by a factor of 0.78 to convert the gauge reading to actual pressure.
  • a satisfactory active ingredient-containing tablet generally should have a hardness in this test of at least about 4 kg.
  • Friability a measure of the tendency of tablets (average of 10 or more tablets) to crumble and dust, expressed in terms of percent weight loss, as determined by the Roche" test described in the Journal of the American Pharmaceutical Association, Scientific Edition, Vol. 45 pages 114-1 16 (1956).
  • an active ingredient-containing tablet displaying a weight loss of less than about 1.0 percent generally is considered to have acceptable friability.
  • Disintegration time the time observed for tablets (range of six tablets) to disintegrate in water as determined by a modification, in which the use of discs is eliminated, of the procedure for uncoated tablets described in Pharmacopeia of the United States of America, 16th Edition, 934-936 (1960).
  • the starting starch suitably may be any granular starch derived from the root, stem, or fruit of a plant.
  • starch-yielding sources include com, rice, wheat, potato, tapioca, and arrowroot.
  • the starting starch raw material suitably may be unmodified, modified, derivatized, or cross-linked. Examples of unmodified starches are the granular starches conventionally prepared from natural starch sources by removal of fiber, gluten, and other proteinaceous impurities, with or without subsequent washing, drying, screening, bleaching, and/or sterilization.
  • Modified granular starches include thin-boiling starches made by heating a water slurry of an unmodified starch below the gelatinization temperature with a mineral acid (e.g. hydrochloric acid) or an oxidizing agent (e.g. alkaline hypochlorite).
  • Derivatized granular starches include starch esters, e.g. starch acetate and starch propionate, and starch ethers, e.g. hydroxyethyl, carboxymethyl, and cyanoethyl starch, prepared from unmodified or modified granular starches with retention of the granular structure.
  • Granular cross-linked starches include ungelatinized starch products made by reacting an unmodified, modified, or derivatized granular starch with a polyfunctional reactant, e.g. phosphorous oxychloride or epichlorohydrin.
  • a polyfunctional reactant e.g. phosphorous oxychloride or epichlorohydrin.
  • the freeflowing property of the compacted starch powders employed in the invention is exemplified by the ability of the powders to meet the following arbitrary test: a sample of powder being tested is poured into a 24/40 standard taper glass powder funnel, the tip of which is suspended normal to, and one inch above, a horizontal, dry, smooth paper surface. Powder is poured through the funnel until the cone of powder formed on the paper surface below reaches the tip of the funnel, and the funnel plugs. The average radius of the cone base is determined by taking four radius measurements from the funnel tip along diameters intersecting at right angles and averaging the values.
  • the angle formed by the inclined surface of the powder cone and the horizontal can be determined using wellknown trigonometric principles, i.e. by calculating the tangent of the angle of repose.
  • a powder which is not free-flowing in the sense of the term as employed herein displays an angle of repose in this test of more than about 40
  • the more preferred free-flowing characteristics are displayed by compacted starch powders forming an angle of repose in the range of from about 20 to about 35.
  • compacted starch powders derived from corn starch, and more preferably an unmodified corn starch constitute the binder-disintegrant ingredients preferred for utilization in the present invention.
  • Such starch raw materials moreover, provide resultant binder-disintegrant ingredients which display excellent color stability during storage and in the ultimate tablet.
  • the particularly preferred binder-disintegrant ingredients are superficially dry, free-flowing powders of the above-described type characterized by a cold-water solubility of from about 6 to about 15 percent and a swelling power of from about 5 to about 8 and being derivatives of a bleached native corn starch, e.g. hypochlorite-bleached native corn starch.
  • the starch binder-disintegrant ingredients employed in the present invention are prepared from the starting granular starch raw materials by the same basic steps heretofore utilized in preparing powders of compacted starches and in general involving compacting the starting starch raw materials in the presence of water, comminuting the resultant compacted material, and classifying the comminuted intermediate into the desired particle size fraction.
  • the compaction step suitably may be carried out in any convenient device conventionally employed for this purpose.
  • the more commonly used devices include differential roll mills, concurrent roll mills, extruders, and the like.
  • the moisture content of the granular feed starch and the temperature which the starch attains during the compaction are important variables in achieving a suitably modified compact.
  • temperatures should be limited to those below the gelatinization temperature of the particular starch used. Higher temperatures provide compacts which, when comminuted, yield powders which are overgelatinized and have poor disintegrant properties.
  • Optimum compaction conditions generally include temperatures in the range of from about 20 to about 50 C.
  • the water content of the granular starch feed must be in the range whereby the properties of the granular starch feed are altered to the desired degree in the compaction treatment.
  • limits for the moisture content will exist at which the starch feed is either too dry or too wet for the compaction to sufficiently change the properties of the starting starch.
  • the operable and optimum water content ranges easily may be determined in the manner known and described hereafter, i.e., varying the feed starch moisture content and noting the degree of starch modification achieved in terms of the effect on the cold-water solubility and swelling power of the starch.
  • water content in the feed granular starch in the range of from about 20 to about 50 per cent of the starch total weight is used to achieve the desired amount of compaction.
  • the lower moisture levels in this range e.g. from about 20 to about 30 percent, are generally more adapted for use in roll-type compaction equipment such as differential roll mills, and the higher water contents in this range, e.g. from about 30 to about 50 percent, are better adapted for use in devices effecting the desired working in a confined space such as in a screw-containing barrel-type extruder.
  • commonly available granular starches generally have a moisture content on the order of 10-12 percent, water usually must be added to the granular feed starch prior to compaction.
  • Another particularly useful compaction technique utilizes a rotating pellet mill which is adapted to subject the starch feed to the sufficient amount of working during the formation of pellets therefrom.
  • An example of a typical pelletting operation which achieves suitable compaction generally employs a pellet mill having dies 3/16 inch in diameter and 1% inches in length in which the starting granular starch at a moisture content of from about 20 to about 30 percent by weight is pelletized at a feed rate of 900 to 1,000 lbs. per hour with the mill rotating at 125-150 r.p.m.
  • Advantages of utilizing a pellet mill are that one pass through the mill usually is sufficient to provide the desired starch modification and that a significantly reduced amount of fines is produced as compared to most other compaction techniques.
  • the material produced by the required amount of compaction then is ground and screened to a suitable particle size, the moisture content being adjusted during the recovery of the desired powder from the compact.
  • the compact is dried prior to being ground. Drying lessens the proportion of fines produced in the grinding step and guards against possible further undesirable starch alteration during grinding. in the drying, the moisture content of the compacted material is commonly reduced to from about 4 to about l4 percent by weight.
  • the grinding suitably may be carried out in any grinder, mill or combination of comminuting devices adapted to reduce the compact to a free-flowing, directly compressible powder. It
  • the more suitable tablet binder-disintegrant powders are those which are relatively fine. ln the grinding step, therefore, the compacted starch generally is reduced to a powder of which at least about 30 percent of the total weight thereof is material of 270 mesh.
  • the term mesh refers to the U.S. Standard Sieve Series, A.S.T.M. specifications. The presence of too great a proportion of fines is not conducive to optimum tabletting so it generally is preferred to control grinding to provide a powder containing less than about 90 percent by weight material of 270 mesh.
  • the more preferred powders obtained in the grinding step are those ground to from about 45 to about 75 percent by weight material of 270 mesh.
  • a specific grinding technique suitable for use involves initially grinding the compact to l mesh and then completing grinding in a mill adapted to recycle all +100 mesh material.
  • the water content of the compacted starch powder has an effect on the binder-disintegrant properties of the material. Too low or too high a water content detracts from the properties of the ultimate tablets formed. Generally moisture contents in the range of from 9 to about 16 percent of the powder total weight are suitable with the more preferred results usually being obtained at moisture contents in the range of from about ll to about 13 percent by weight. Accordingly, following grinding, the moisture content of resultant powder preferably is adjusted, if necessary, by drying or the addition of water.
  • the binder-disintegrant starch powders preferred for use contain a low proportion of coarse particles. Generally, it is desired that the powder contains less than about percent by weight material of +80 mesh. The more preferred powders are essentially free of +40 mesh material Proportion of Powder,
  • an active material ingredient is thoroughly mixed by any suitable dry blending technique with one or more of the above-described compacted starch powders in 7 relative amounts required to provide a resultant superficially dry, freeflowing formulation directly compressible into tablets, and the fonnulation then is tabletted by direct compression.
  • Active ingredients contemplated to be employed in the preparation of tablets by the present invention constitute all active ingredients compatible with the above-described compacted starch powders in formulations directly compressible into tablets.
  • the present invention is particularly adapted for use in preparing tablets containing pulverulent pharmaceuti cally active materials.
  • Specific examples of pharmaceutically active ingredients which advantageously may be tabletted by the present invention include ascorbic acid, sodium paminosalicylate, phenacetin, and N-acetyl-p-aminophenol, all materials which heretofore generally have been tabletted only with great difficulty.
  • the particular nature of the active material is not critical, however, and nonpharmaceutical active materials, e.g. pulverulent detergents, dyes, pesticides, and foods, forming directly compressible mixtures with the compacted starch powders can also be employed.
  • the amount of active material ingredient employed in preparing tablets according to the present technique depends, inter alia, upon the nature and relative compatibility of the active material, and the end use for which the tablet is desired, the latter dictating thereby the tolerable properties in terms of hardness, friability, and/or disintegratability of the final tablet. Given the minimum and preferred characteristics desired in the final tablet, the tolerable limits on the weight ratio of active ingredient to binder-disintegrant for a particular active ingredient easily may be determined by the known technique of sequentially increasing the active ingredient content of the tablet.
  • acceptable active material-containing tablets are those which display a hardness of at least about 4 kg., preferably above about 5 kg., and a friability corresponding to a weight loss of less than about l.0 percent, preferably less than about 0.5 percent.
  • a lower hardness generally can be tolerated.
  • the disintegration requirements may vary over a wide range.
  • a particular feature of the present invention is that a wide range of active ingredients may be tabletted to provide tablets displaying disintegration times in aqueous media of generally less than 30 minutes and more usually less than 15 minutes and in the range of from about 0.5 to about l0 minutes.
  • the rapid disintegration rates of tablets prepared by the present method stem from the advantageous characteristics of the compacted starch powders to function not only as excellent binding agents but as agents which accelerate tablet disintegration as well.
  • specific embodiments of tablets prepared in the invention contain from about 5 to about 90 percent by weight active ingredient, dry substance basis.
  • An additional feature of the present invention is that, by the use of the binder-disintegrant compacted starch powders, even many pulverulent active ingredients which themselves are noncompressible or only poorly compressible, exemplified by the pharmaceuticals named, may be formed into suitable tablets containing from about 20 to about 50 percent and above of the active ingredient based on the tablet dry substance weight.
  • Adjuvants such as tabletting lubricants, fillers, antisticking agents, coloring agents, and the like, conventionally employed in preparing particular tablets by direct compression, suitably may be incorporated in appropriately effective amounts into the compressible formations formed in the present invention.
  • a lubricant such as talc, magnesium stearate, or stearic acid, when employed, generally is added in an amount ranging up to about percent by weight of the total tabletting formulation.
  • Colloidal silica constitutes a typical antisticking agent or socalled glidant.”
  • a glidant such as colloidal silica, when incorporated in a formulation, usually is added in an amount ranging up to about 2 percent of the formulation total weight.
  • Fillers which may also function as supplemental binders or disintegrants, where employed, must not be added in amounts which impair undesirably the direct compressibility of the tabletting formulations.
  • the present invention is capable of satisfying the dual requirements of a binder-disintegrant
  • the present invention also contemplates embodiments wherein efiective amounts of another direct compression binder such as lactose and the like and/or a separate disintegrating agent such as native cornstarch also is incorporated into the formulation.
  • efiective amounts of another direct compression binder such as lactose and the like and/or a separate disintegrating agent such as native cornstarch also is incorporated into the formulation.
  • the addition of such additional binders is unimportant in view of the excellent characteristics of the binder-disintegrant compacted starch powder of this invention.
  • the present invention is directed primarily to embodiments wherein the superficially dry, free-flowing binder-disintegrant starch of this invention is the major binder ingredient employed, i.e.
  • a supplemental disintegrant may provide some improvement.
  • An example of this is in the preparation of tablets of sodium p-amino-salicylate dihydrate wherein the disintegration rate of the tablet advantageously may be further accelerated by the addition of a conventional granular starch disintegration aid.
  • the more desirable tablets are prepared from superficially dry formulations containing from about 5 to about percent moisture based on the formulation total weight. Accordingly, appropriate adjustment of the moisture content may be made, where necessary or desirable, during the formulation operation to improve the tabletting characteristics of the mixture. It may also be desirable, after mixing the ingredients, to screen the formulation to remove any oversize particles introduced in the active ingredient or tabletting aids and thereby to improve tabletting efficiency. In this respect, removal of +40 mesh particles by screening generally is desirable.
  • any conventional single or rotary tablet making apparatus suitably may be employed in the tabletting operation.
  • tabletting operation As is standard in conventional tabletting practice, optimum results are obtained for particular formulations by the use of the highest pressure settings consistent with good tablet press operation.
  • Tablets prepared from a given batch of tabletting formulation by means of the present invention are essentially uniform in thickness, weight, and active ingredient dosage level and have excellent surface smoothness as indicated by the lack of pits and cracks.
  • a further characteristic of the tablets made according to the invention is that a substantial duplication of tablet properties is obtained by grinding the tablets to a freeflowing powder and retabletting.
  • EXAMPLE I This example illustrates the preparation of suitable tablet binder-disintegrant starches from an unmodified cornstarch and the use of the binder-disintegrant starches in the preparation of tablets by direct compression.
  • the dried pellets were then ground to -10 mesh in a Model DS-6 Series [606 stainless steel Fitzmill grinder, and the l0 mesh material was further ground to l00 mesh in a Model PC 20 Strong-Scott Pulvocron grinder operated at 3,500 r.p.m. with the classifier at 1,000 r.p.m. and the tailings return at 100 percent.
  • the resultant powder was remoistened to l 1.5-] 2.5 percent by weight water in a horizontal ribbon blender, and the moistened material was screened to 40 mesh.
  • the properties of the resultant compacted starch powder (starch A,,) are set forth in table 1.
  • starch A had the properties set forth in table I bonlike compact obtained was dried to 7 percent by weight water and then ground as in technique 2 above. The ground material was then adjusted to a moisture content of about 12.0 percent by weight, and then finally screened to 80 mesh.
  • the properties of the resultant compacted starch powder (starch).
  • the compacted starch powders are directly compressible into tablets themselves and that suitably hard, nonfriable, rapidly disintegrative tablets containing relatively high levels of heretofore difiicult-to-tablet drugs, i.e. ascorbic acid, phenacetin, and APAP, advantageously can be prepared using the compacted starch powders as sole dual-functioning binder-disintegrant ingredients.
  • the NaPAS-containing tablets disintegrated relatively slowly, these tablets had suitable hardness and friability properties; the compacted starches are satisfactory binders even of this previously difficult-to-tablet drug.
  • EXAMPLE ll Ac are Set forth in table in order to compare the binder-disintegrant properties of TABLE 1 Coldwater Loose Flow- H2O solu- Swellbulk ability, content, bility, ing density, angle of Starch Description percent percent; power gun/ml. repose
  • the data in table 1 indicates that the three different comthe compacted starch powders employed in the present invenpaction methods can each produce compacted starch powders, ssentially equivalent in these properties.
  • Superficially dry tabletting formulations were prepared by thoroughly blending the resultant compacted starch powders each in turn, with separate powdered preparations of ascorbic acid, phenacetin, sodium p-amino-salicylate dihydrate (NaPAS) a N-acetyl-p-aminophenol (APAP) in the proportions set forth below in table 2, incorporating talc and/or colloidal silica (Cab-o-Sil) as tabletting aids into the formulations, and screening the resultant mixtures to mesh.
  • the 40 free-flowing powders obtained were then directly tabletted on a Colton No. 204 four-punch press manufactured by the Colton Division of Cherry-Burrell Corporation, Detroit, Mich. A set of inch diameter standard cap punches and dies was employed, and the press was operated at 35 rpm. to produce tabletted using the same tabletting procedure.
  • the properties of the tablets obtained also are set forth in table 2.
  • the starting bleached native cornstarch (starch A) of example I was converted to a compacted starch powder using technique 3 of example with the exception that the moisture content of the starting starch was initially adjusted to about l8 percent by weight so that the starch was worked and modified to a lesser degree.
  • the resultant compacted starch powder was characterized by a 2.9 percent cold-water solubles content, a swelling power of 3.0, a loose bulk density of 0.49 gm./ml., and flowability corresponding to an angle of repose of more than 40.
  • the resultant compacted starch powder was tabletted alone using the procedure of example I.
  • the tablets obtained had an average hardness of 3 kg., a friability corresponding to an average weight loss of L93 percent, and a disintegration time in water of 0.5-1 .5 minutes.
  • the low cold-water solubles content powder is not suitable for use as a sole dual-functioning binder-disintegrant ingredient in preparing acceptable tablets by direct compression.
  • EXAMPLE m This example illustrates the preparation of suitable tablet .binder-disintegrant starches from oxidized cornstarch and the use of the resultant binder-disintegrant starches in the preparation of tablets by direct compression.
  • This example illustrates the preparation and use of a tablet binder-disintegrant starch derived from an acid-modified starch raw material.
  • starch E having an alkali fluidity of about 62 cc. g. starch, as is basis, 77 F. and 0.375 N sodium hydroxide
  • a compacted starch powder employing technique 2 (differential roll-milling) of example I except that the starch feed moisture content utilized was 28.0-30.5 by weight, the roll gap was 6'mils, and the roll temperature was maintained at 23-26 C.
  • a comparison of the properties of the starting granular starch and the resultant compacted starch powder (starch E obtained are set forth in table 3. Following the tabletting procedure of example I, placebo tablets (without drugs) were prepared using the compacted starch powder alone. The properties of the tablets obtained are reflected in table 4.
  • EXAMPLE Vll This example illustrates the preparation an use of a tablet binder-disintegrant starch obtained from a derivatized granular starch raw material.
  • a granular derivatized cornstarch containing about 2.5 percent acetyl groups (starch F) was converted to a compacted starch powder using technique 2 (differential roll-milling) of example 1 except that the feed starch moisture content was 28.3-3l percent by weight, a roll gap of 12 mils was employed, and roll temperatures were maintained at 23-24 C.
  • the properties of the starting starch and the resultant compacted starch powder (starch F are set forth in table 3.
  • placebo (drugfree) tablets were prepared from the compacted starch powders. The properties of the tablets are shown in table 4.
  • the compacted starch powder When substituted as the binder-disintegrant ingredient in the preparation of the drug-containing tablets described in the preceding examples, the compacted starch powder provides tablets of properties comparable to those mentioned.
  • EXAMPLE Vlll This example illustrates the preparation and use of a tablet binder-disintegrant starch obtained from a cross-linked granular starch raw material.
  • example VI The procedure of example VI was repeated with the exception of substituting a granular cross-linked cornstarch obtained by reacting oxidized cornstarch with phosphorus oxychloride (starch G) for the acid-modified starch.
  • the properties of the starting starch and resultant compacted starch powder (starch G are set forth in table 3.
  • the characteristics of the tablets obtained are shown in table 4.
  • Drugcontaining tablets prepared by direct compression, using the resultant compacted starch powder as a binder-disintegrant ingredient as in the preceding examples, have characteristics similar to such tablets described above.
  • EXAMPLE IX This example illustrates the preparation and utilization of a tablet binder-disintegrant starch derived from potato starch.
  • example Vll The procedure of example Vll was repeated except that native potato starch (starch H) was substituted for the derivatized cornstarch.
  • native potato starch starch H
  • a comparison of the properties of the starting starch and the resultant compacted starch powder starch H is shown in table 3, and the characteristics of the placebo tablets prepared therefrom are listed in table 4.
  • the resultant compacted starch powder provides acceptable tablets.
  • EXAMPLE x This example illustrates an embodiment of the present invention wherein a binder-disintegrant starch is employed in combination with an uncompacted starch in the preparation of active ingredient tablets by direct compression, the uncompacted starch being employed as a filler and disintegrant ingredient in the tablets.
  • starch D differentiated native cornstarch
  • NaPAS sodium p-aminosalicylate dihydrate
  • Cab-o-Sil colloidal silica
  • the resultant powder which had a moisture content of 12.1 percent by weight was tabletted directly using the procedure of example I.
  • the resultant tablets were characterized by an average hardness of 8.7 kg., a friability corresponding to an average weight loss of 0.24 percent, and a disintegration time of 20-26 minutes.
  • EXAMPLE Xl This example illustrates embodiments of the present invention wherein a binder-disintegrant starch is employed in the preparation of tablets by direct compression wherein the tablets are intended for nonpharmaceutical uses.
  • starch A (pelletized bleached native cornstarch) described in example I as the binder-disintegrant ingredient and the tabletting procedure of example 1
  • tablets that disintegrate rapidly in water and have excellent hardness and friability properties are prepared from the following formulations:
  • oxidized starch used in sample 1 l is a corn starch oxidized by sodium hypochlorite under alkaline conditions until it has about 0.5 percent carboxyl groups.
  • Sample 1, 2, 7, 8, 9 and 10 which were not compacted and which did not fall within the parameters set forth on page 7 with respect to at least two of cold-water solubility, swelling power, loose bulk density, and moisture content, could not be tabletted.
  • a directly compressed tablet requiring a disintegrant and a binder, having resistance to breaking and crumbling, and being capable of disintegrating in an a ueous medium
  • said tablet comprising (a) an active ingredten by which said tablet derives its utility and (b) a pulverulent cohesive binder for said active ingredient, said binder comprising as the only dualfunction binder and tablet-disintegrant a directly compressible compacted starch powder in a concentration that provides substantial binding action and substantially accelerates disintegration of said tablet in an aqueous medium, said compacted starch powder being a superficially dry, free-flowing material in which the starch is in the form of a mixture of birefringent granules and nonbirefringent fragments of granules, in which some aggregates of granules and fragments are present and having a cold-water solubility in the range of from about 4 to about 40 percent by weight, dry substance basis, a swelling power in the range of from about 2.5 to about
  • said compressed tablet according to claim 1 wherein said compacted starch powder constitutes at least about 50 percent of the total weight amount of binder in said tablet, has a cold-water solubility in the range of from about 6 to about 20 percent, dry substance weight basis, and a swelling power in the range of from about 3.5 to about 10, and contains, on a total weight basis, from about 45 to about 75 percent of material which is -270 mesh.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

A directly compressed tablet containing as a binder-disintegrant ingredient, a partially cold-water soluble, cold-water swelling starch material derived from compacted granular starch, e.g. compacted native corn starch. The compacted granular starch is a superficially dry, free-flowing powder in which the starch is in the form of a mixture of birefringent granules and nonbirefringent fragments of granules, in which some aggregates of granules and fragments are present. The use of the starch binder-disintegrant ingredient allows active ingredients, e.g. pharmaceuticals, to be tabletted by direct compression.

Description

[21] Appl. No.
United States Patent Rolland W. P. Short;
Frank Verbanac, both of Decatur, Ill. 839,590
July 7, 1969 Nov. 23, 1971 A. E. Staley Manufacturing Company Decatur, lll.
Continuation-impart of application Ser. No. 646,496, June 16, 1967, now abandoned. This application July 7, 1969, Ser. No. 839,590
[ 72] Inventors [22] Filed [45] Patented [73] Assignee {54] ,,COMPRESSED TABLETSCONTAINING COMPACTED STARCH AS BINDER- DISINTEGRANT INGREDIENT 8 Claims, 4 Drawing Figs.
52 U.S. c1. 424/361, 106/210, 424/229, 424/230, 424/280, 424/300, 424 324, 252/1;99, 71/77, 99 140, 8/79, 264/1 18,
, 127/32 [51] Int. Cl A61] 3/10 [50] Field of Search 424/361;
[56] References Cited UNITED STATES PATENTS 3,034,911 5/1962 McKee et a1 106/210 3,101,299 8/1963 Ferrand 424/361 X 3,424,842 1/1969 Nurnberg 424/94 3,453,368 7/1969 Magid 424/280 3,490,742 1/1970 Nichols et al. 252/99 Primary Examiner-Shep K. Rose Attorney-Charles J. Neyerson ABSTRACT: A directly compressed tablet containing as a binder-disintegrant ingredient, a partially cold-wa ter soluble,
COMPRESSED TABLETS CONTAINING COMPACTED STARCI-I AS BINDER-DISINTEGRANT INGREDIENT CROSS-REFERENCE This application is a continuation-in-part of application Ser. No. 646,496, filed June 16, 1967 now abandoned.
DISCLOSURE OF THE INVENTION This invention relates to the manufacture of compressed tablets and more particularly to compressed tablets which contain a starch binder-disintegrant ingredient in the form of a directly compressible compacted starch powder which permi the tablets to be made by the direct compression technique.
.Of the multitude of forms in which pharmaceutical products may be dispensed, the compressed tablet form is, by far, that most frequently employed today. Ease of packaging and handling, and, most important accuracy of dosage in administration are among the advantages stemming from the use of medicament-containing tablets. For essentially the same reasons, the compressed tablet also plays an important role in other fields as a dispensing unit. Examples of nonpharmaceutical materials marketed in compressed tablet form include such diverse materials as laundry detergents, confections, artificial sweeteners, fish foods, plant growth regulators, pesticides, herbicides, and dyes. While the actual characteristics of various tablets differ depending on the particular nature and planned use of the several tablets, the generally more important characteristics fall into three areas of consideration.
Since most tablets are designed for use in accurately dispensing an active material into a fluid medium, an evaluation of the tablet includes a consideration of the tablet disin tegration properties in the fluid medium. While some tablets such as those designed for use as a throat lozenge desirably are slowly disintegrative in the fluid medium in which they are placed for use, in most cases rapid disintegration of the tablet is desired. For example, a tablet embodying an ingestible analgesic, such as aspirin, should rapidly break down in the digestive fluid of the stomach to make the active ingredient promptly available to the organism. The present invention is particularly concerned with such tablets of relatively rapid disintegration capability.
The second and third important tablet characteristics, friability and hardness, are somewhat related in that as tablet hardness increases the friability of the tablet generally decreases. Excessive friability is undesirable since dusting and crumbling of the tablet results in at least some diminution in active ingredient dosage, detracts from the tablet appearance and consumer appeal, and reduces the effectiveness of any tablet markings. insufficiently hard tablets, in addition to exhibiting the efl'ects of excessive friability, are prone to breakage and chipping, particularly in transport where they may be subjected to repeated mechanical shock.
Accordingly, for most purposes, and particularly for pharmaceutical application, a hard, nonfriable tablet possessing acceptable disintegration characteristics is the goal of the tablet manufacturer. Other properties are, of course, important such as color stability and nonhygroscopicity but the desideratum remains the production of a tablet of the type described.
Certain materials such as sodium chloride, paradichlorobenzene, hexamethylenetetramine, and certain medicaments are readily directly compressed alone in dry form into a firm, coherent mass in a tablet machine. However, the majority of active ingredients in order to be tabletted require a binding agent to be added. The tabletted formulations generally also contain additional ingredients, such as lubricants, disintegrants, fillers, colorants, and the like. The terms binding agent," binder," and filler" are self-explanatory. A disintegrant is an agent which is effective, when the tablet is placed in the proper fluid environment, to promote destruction of the tablet's physical integrity. A typical disintegrant employed in tabletting is granular starch.
A given material may perform more than one of the single functions of binding, filling, and promoting disintegration. The principal component, other than the active ingredient, that is employed to provide the improved compressed tablets of the present invention is such a dual-functioning material and is referred to herein as a binder-disintegrant.
In general, three methods are known for the preparation of mixtures suitable to be employed in a tablet-making machine. In two of the methods commonly used for the preparation of tabletting machine feed material, the goal in each is the preparation of the feed material in the form of free-flowing granules. One technique involves a dry, and the other a wet, method of granulation. Dry granulation is also referred to as slugging or double compression. In accordance with the slugging technique, thejnitially prepared.pulverulentadmixture of active ingredient, filler, binder and the like is formed into large tablets or slugs by dry compression molding. These slugs are then milled to granules of predetermined size adapted to be used as the feed to the tablet-making machine. This method is expensive, requiring considerable equipment, labor, and power. The technique, moreover, does not always provide suitable tablets.
The wet granulation technique involves adding a moistening agent such as water or ethylene glycol to the tabletting in gredient mixture to prepare a moistened mass, oven drying the wetted mass, and milling the dried mass into granules adapted to be used in the tabletting machine. The wet granulation method likewise is undesirably time consuming and expensive. This method, moreover, has the limitation of not being useful when the tablet ingredients are incompatible to wetting or are heat sensitive.
The third and simplest procedure employed in preparing tabletting formulations involves intimately and uniformly dry blending the ingredients employed, e.g. active ingredient, binder, filler, disintegrant, and lubricants, to provide a pulverulent mixture displaying the requisite flowability for adequate feeding to the tablet machine. Since in this method the granulation step is eliminated, the formulations are said to be directly compressible" into tablets, and the tablet-forming operation is referred to as direct-compression" tabletting. This procedure, by virtue of its simplicity, obviously is preferred for use. Using ingredients heretofore available, however, the ingredient mixtures obtained by mere dry mixing generally do not exhibit adequate flowability and are not adapted to be fed directly to the tabletting machine to prepare tablets of uniform and acceptable properties. The limited acceptance of preparing compressed tablets by direct compression has stemmed principally from the unavailability of suitable and inexpensive direct compression binding agents. Of those materials which do qualify by reason of their binding properties, moreover, few are characterized by satisfactory overall properties. For example, the most widely used material at present for binding tablets by the direct compression method, spray-dried lactose, is unacceptable in many uses because of its marked tendency to turn brown on aging. The great percentage of tabletting operations, therefore, have been forced to resort to other fonnulation techniques such as the wet and dry granulation methods, and the art has continued to search for an improved material capable of being employed as a binder in the preparation of tablets by direct compression which are rapidly disintegrative, resistant to breakage and crumbling, and otherwise satisfactory.
Accordingly, it is an object of the present invention to provide an improved binder for the manufacture of compressed tablets. It is another object of the invention to provide such an improved binder having characteristics that permit it to function also as a disintegrant. it is an additional object of the invention to provide active ingredient, binder ingredient formulations directly compressible into tablets. It is yet a further object of the invention to provide a compressed tablet containing a binder-disintegrant ingredient, the tablet being hard, nonfriable, and readily disintegrative in an aqueous medium. Yet another object of the invention is to provide a method for preparing compressed tablets. A particular object of the present invention is to provide a means whereby tablets of ex cellent properties can be prepared by direct compression. The means of attaining these and related objects will be evident from the following description and examples.
For a more complete understanding of the nature and scope of the invention reference may now be had to the following detailed description thereof with illustrative working examples, and to the accompanying drawings, wherein:
FIG. 1 is a photomicrograph, taken under bright field illumination of ordinary corn starch at a magnification of 425;
FIG. 2 is a photomicrograph corresponding to FIG. 1 but with the light polarized;
r it]. 3 is a photomicrograph, taken under bright field illumination of compacted corn starch, useful in accordance with the present invention, at a magnification of 425; and
FIG. 4 is a photomicrograph corresponding to FIG. 3 but with the light polarized.
Compacted starches constitute a known class of materials. They are prepared by subjecting a granular starch raw material to pressure in the presence of water to effect distortion and fracture of at least some of the granules and produce adhesion between particles of the resultant mass. The resultant compacted material may have differing cold-water swelling properties and contain varying amounts of cold-water soluble material depending primarily upon the particular pressure, temperature, and moisture conditions utilized. Specific techniques commonly employed include passing the starting starch through the nip of rotating rolls operating at the same or different speeds, as described in US. Pat. Nos. 2,098,293; 2,168,524; 2,464,081; and 3,196,044, and working the starch in the course of an extrusion operation as shown in US. Pat. Nos. 3,137,592 and 3,159,505. Compacted starches heretofore have found utility primarily as dustless carbohydrate nutrients in the brewing industry and as binders in the preparation of rough-molded products containing relatively coarse aggregate materials such as foundry cores and charcoal briquettes.
It now surprisingly has been discovered that certain compacted starch powers, described more fully hereinafter, advantageously are characterized by properties which enable them to be dry mixed with active ingredients and conventional tabletting aids, such as fillers, lubricants, and the like, to prepare active ingredient-containing formulations which are directly compressible into tablets in conventional tabletting equipment. The present invention therefore provides a highly valuable means whereby tabletting operations may be greatly simplified, and the troublesome and time-consuming preliminary granulation and slugging steps which characterized most tabletting operations heretofore available may be eliminated. The compacted starch powders employed in the present invention, moreover, advantageously are characterized by properties which satisfy both the requirements of a binder for the active ingredient and a disintegrant for the tablet in aqueous media. Consequently, suitable direct compression tablets of satisfactory hardness, friability, and disintegration properties advantageously may be prepared by means of the present invention using the compacted starch powders as a sole, dualfunctioning binder-disintegrant, and the heretofore commonly required practice of adding separate ingredients as the binder and disintegrant with the attendant problems of properly mixing multiple ingredients and balancing dosage levels no longer need be followed. The starch binder-disintegrant ingredient employed in preparing direct compression tabets in accordance with the present invention, furthermore, easily and cheaply may be obtained from readily available and inexpensive starting raw materials, namely granular starches. Of such binder-disintegrant compacted starches many embodiments are characterized by low color, color stability, and acceptability for human consumption. The present invention, therefore, includes what may be said to be a universal" ingredient for direct compression tabletting, whereby a wide range of active ingredients, including many pharmaceuticals tabletted heretofore only with great difficulty, if at all, now easily and inexpensively may besatisfactorily tabletted by direct compression.
The compacted starch powders employed in the practice of the present invention are derived from appropriately compacted granular starch raw materials and are superficially dry, free flowing, partially cold-water soluble materials which swell in cold water and have a relatively high loose bulk density. The powders themselves are directly compressible in conventional tabletting equipment into relatively rapidly disintegrative placebo tablets of high hardness and low friability. Microscopic examination of the compacted starch powders reveals the starch content of the materials to be in the form of a mixture of birefringent granules and nonbirefringent fragments of granules, in which some aggregates of granules and fragments are present. These characteristics of the compacted starch powders on microscopic examination are apparent from the photomicrographs reproduced in FIGS. 1-4. In FIG. 1 granules of ordinary corn starch are shown as viewed with unpolarized light at 425 magnification. FIG. 2 shows the same granules viewed with the light polarized at the same magnification. It will be noted that in FIG. 2 the granules all exhibit birefringence (i.e. the crosses) which is characteristic of starch granules.
In FIG. 3 a sample of compacted starch powder, which is directly compressible into tablets in accordance with this invention, is shown as viewed with unpolarized light at 425 magnification. A number of starch granules appear in F IGv 3 along with aggregates and granular fragments. When the same sample of compacted starch powder is viewed under polarized light at the same magnification, it is clearly seen that the sample is a mixture of birefringent granules and nonbirefringent fragments of granules, in which there are aggregates of granules and fragments.
Compacted starch powders of the invention have the following characteristics:
As used herein, the term superficially dry is intended to indicate a powder is dry in the visual and tactile sense. A placebo tablet is a tablet prepared by directly compressing one material alone such as a compacted starch powder. The terms cold-water solubility, swelling power, hardness," friability," disintegration time, and granular starch raw material are defined as follows:
Cold-water solubility-The percent by weight of the starch dry substance which dissolves in water at 25 C. when determined by the following procedure: One gram of the starch product being. tested is added to ml. of water at 25 C. in a high-shear blender and mixing is carried out at 1,500 r.p.m. for 2 minutes. The resultant sample is then transferred to a 250 ml. round-bottom centrifuge tube and centrifuged for 15 minutes at 2,000 r.p.m. A 25 ml. aliquot of the clear centrifugate is transferred to a tared aluminum pan and evaporated to dryness on a steam bath. The dish is then dried to a constant weight at 1 10 C. The weight of the dried material in the pan multiplied by 400 and divided by the dry substance weight of the original sample is the cold-water solubility of the starch material. By this test commonly available granular starches are essentially cold-water insoluble, generally containing less than about 2 percent by weight cold-water solubles and in the case of unmodified starches less than about 1 percent.
Swelling power-a measure of the ability of a starch to swell in cold water as determined by method 56-20 of Cereal Laboratory Methods" published by the American Association of Cereal Chemists. For reference purposes, uncompacted granular starches generally have a swelling power on the order of about 2.
Hardnessa measure of the strength of tablets (average of or more tablets) and their ability to retain their physical integrity, expressed in terms of kilograms, as determined by the conventional procedure using a model B tablet hardness tester of the Strong-Cobb-Amer Company, Cleveland, Ohio, to obtain an indicated pressure gauge reading at fracture of the tablet (tablet mounted on edge in tester) and multiplying the indiczwu hardness value by a factor of 0.78 to convert the gauge reading to actual pressure. For example, a satisfactory active ingredient-containing tablet generally should have a hardness in this test of at least about 4 kg.
Friability-a measure of the tendency of tablets (average of 10 or more tablets) to crumble and dust, expressed in terms of percent weight loss, as determined by the Roche" test described in the Journal of the American Pharmaceutical Association, Scientific Edition, Vol. 45 pages 114-1 16 (1956). For reference purposes, an active ingredient-containing tablet displaying a weight loss of less than about 1.0 percent generally is considered to have acceptable friability.
Disintegration time-the time observed for tablets (range of six tablets) to disintegrate in water as determined by a modification, in which the use of discs is eliminated, of the procedure for uncoated tablets described in Pharmacopeia of the United States of America, 16th Edition, 934-936 (1960).
Granular starch raw material-the starting starch which has been compacted in the preparation of the compacted starch powders of the invention. The starting starch suitably may be any granular starch derived from the root, stem, or fruit of a plant. Specific examples of starch-yielding sources include com, rice, wheat, potato, tapioca, and arrowroot. The starting starch raw material suitably may be unmodified, modified, derivatized, or cross-linked. Examples of unmodified starches are the granular starches conventionally prepared from natural starch sources by removal of fiber, gluten, and other proteinaceous impurities, with or without subsequent washing, drying, screening, bleaching, and/or sterilization. Modified granular starches include thin-boiling starches made by heating a water slurry of an unmodified starch below the gelatinization temperature with a mineral acid (e.g. hydrochloric acid) or an oxidizing agent (e.g. alkaline hypochlorite). Derivatized granular starches include starch esters, e.g. starch acetate and starch propionate, and starch ethers, e.g. hydroxyethyl, carboxymethyl, and cyanoethyl starch, prepared from unmodified or modified granular starches with retention of the granular structure. Granular cross-linked starches include ungelatinized starch products made by reacting an unmodified, modified, or derivatized granular starch with a polyfunctional reactant, e.g. phosphorous oxychloride or epichlorohydrin.
The freeflowing property of the compacted starch powders employed in the invention is exemplified by the ability of the powders to meet the following arbitrary test: a sample of powder being tested is poured into a 24/40 standard taper glass powder funnel, the tip of which is suspended normal to, and one inch above, a horizontal, dry, smooth paper surface. Powder is poured through the funnel until the cone of powder formed on the paper surface below reaches the tip of the funnel, and the funnel plugs. The average radius of the cone base is determined by taking four radius measurements from the funnel tip along diameters intersecting at right angles and averaging the values. From the cone height (1 inch) and the average radius of its base, the angle formed by the inclined surface of the powder cone and the horizontal, herein referred to as the angle of repose," can be determined using wellknown trigonometric principles, i.e. by calculating the tangent of the angle of repose. A powder which is not free-flowing in the sense of the term as employed herein displays an angle of repose in this test of more than about 40 The more preferred free-flowing characteristics are displayed by compacted starch powders forming an angle of repose in the range of from about 20 to about 35.
Due to the availability and low cost of the starting raw material required, compacted starch powders derived from corn starch, and more preferably an unmodified corn starch, constitute the binder-disintegrant ingredients preferred for utilization in the present invention. Such starch raw materials, moreover, provide resultant binder-disintegrant ingredients which display excellent color stability during storage and in the ultimate tablet. By reason of the excellent overall properties of tablets which can be obtained by the use thereof, the particularly preferred binder-disintegrant ingredients are superficially dry, free-flowing powders of the above-described type characterized by a cold-water solubility of from about 6 to about 15 percent and a swelling power of from about 5 to about 8 and being derivatives of a bleached native corn starch, e.g. hypochlorite-bleached native corn starch.
The starch binder-disintegrant ingredients employed in the present invention are prepared from the starting granular starch raw materials by the same basic steps heretofore utilized in preparing powders of compacted starches and in general involving compacting the starting starch raw materials in the presence of water, comminuting the resultant compacted material, and classifying the comminuted intermediate into the desired particle size fraction.
The compaction step suitably may be carried out in any convenient device conventionally employed for this purpose. As described above, the more commonly used devices include differential roll mills, concurrent roll mills, extruders, and the like. The moisture content of the granular feed starch and the temperature which the starch attains during the compaction are important variables in achieving a suitably modified compact. In preparing compacted starches suitable for use in the present method, temperatures should be limited to those below the gelatinization temperature of the particular starch used. Higher temperatures provide compacts which, when comminuted, yield powders which are overgelatinized and have poor disintegrant properties. Optimum compaction conditions generally include temperatures in the range of from about 20 to about 50 C.
The water content of the granular starch feed must be in the range whereby the properties of the granular starch feed are altered to the desired degree in the compaction treatment. For a given starch and a given compaction device, limits for the moisture content will exist at which the starch feed is either too dry or too wet for the compaction to sufficiently change the properties of the starting starch. For a given starch and compacting device, however, the operable and optimum water content ranges easily may be determined in the manner known and described hereafter, i.e., varying the feed starch moisture content and noting the degree of starch modification achieved in terms of the effect on the cold-water solubility and swelling power of the starch. As a general rule, in most conventional starch compaction equipment, water content in the feed granular starch in the range of from about 20 to about 50 per cent of the starch total weight is used to achieve the desired amount of compaction. The lower moisture levels in this range, e.g. from about 20 to about 30 percent, are generally more adapted for use in roll-type compaction equipment such as differential roll mills, and the higher water contents in this range, e.g. from about 30 to about 50 percent, are better adapted for use in devices effecting the desired working in a confined space such as in a screw-containing barrel-type extruder. Since commonly available granular starches generally have a moisture content on the order of 10-12 percent, water usually must be added to the granular feed starch prior to compaction.
While, as stated above, the particular compaction technique employed in preparing the starches employed as binder-disintegrants in the present invention is not critical, a compaction method which is particularly useful is exemplified by that disclosed in US. Pat. No. 2,464,081 entailing the use of a differential mill. In a typical application of this technique, a granular starch feed having an adjusted moisture content in the range of from about 24 to about 32 percent by weight is fed through the mill operated with a gap between the rolls in the range of 3 to 12 mils. Typical roll speeds vary between 35 to about 70 feet (linear) per minute using a speed differential of from about 10 to about 20 feet per minute. Roll temperatures maintained by circulating water through the rolls generally vary between about 10 to about 40 C. More than one pass through the rolls generally is required to sufficiently modify the starting starch properties with up to four passes being common.
Another particularly useful compaction technique utilizes a rotating pellet mill which is adapted to subject the starch feed to the sufficient amount of working during the formation of pellets therefrom. An example of a typical pelletting operation which achieves suitable compaction generally employs a pellet mill having dies 3/16 inch in diameter and 1% inches in length in which the starting granular starch at a moisture content of from about 20 to about 30 percent by weight is pelletized at a feed rate of 900 to 1,000 lbs. per hour with the mill rotating at 125-150 r.p.m. Advantages of utilizing a pellet mill are that one pass through the mill usually is sufficient to provide the desired starch modification and that a significantly reduced amount of fines is produced as compared to most other compaction techniques.
The material produced by the required amount of compaction then is ground and screened to a suitable particle size, the moisture content being adjusted during the recovery of the desired powder from the compact. For optimum results, the compact is dried prior to being ground. Drying lessens the proportion of fines produced in the grinding step and guards against possible further undesirable starch alteration during grinding. in the drying, the moisture content of the compacted material is commonly reduced to from about 4 to about l4 percent by weight.
The grinding suitably may be carried out in any grinder, mill or combination of comminuting devices adapted to reduce the compact to a free-flowing, directly compressible powder. It
has been found that the more suitable tablet binder-disintegrant powders are those which are relatively fine. ln the grinding step, therefore, the compacted starch generally is reduced to a powder of which at least about 30 percent of the total weight thereof is material of 270 mesh. The term mesh, as used herein, refers to the U.S. Standard Sieve Series, A.S.T.M. specifications. The presence of too great a proportion of fines is not conducive to optimum tabletting so it generally is preferred to control grinding to provide a powder containing less than about 90 percent by weight material of 270 mesh. The more preferred powders obtained in the grinding step, by virtue of the properties of the tablets obtained therefrom and their adaptability to tabletting machine operation, are those ground to from about 45 to about 75 percent by weight material of 270 mesh. A specific grinding technique suitable for use involves initially grinding the compact to l mesh and then completing grinding in a mill adapted to recycle all +100 mesh material.
The water content of the compacted starch powder has an effect on the binder-disintegrant properties of the material. Too low or too high a water content detracts from the properties of the ultimate tablets formed. Generally moisture contents in the range of from 9 to about 16 percent of the powder total weight are suitable with the more preferred results usually being obtained at moisture contents in the range of from about ll to about 13 percent by weight. Accordingly, following grinding, the moisture content of resultant powder preferably is adjusted, if necessary, by drying or the addition of water.
As stated, the binder-disintegrant starch powders preferred for use contain a low proportion of coarse particles. Generally, it is desired that the powder contains less than about percent by weight material of +80 mesh. The more preferred powders are essentially free of +40 mesh material Proportion of Powder,
Particle Size total weight 40-80 mesh 5 -200 mesh 5-30 200-270 mesh l0-40 through 270 mesh 45-75 At least 10 percent should be between 80 and 270 mesh to help in imparting free-flowing characteristics.
In the preferred preparation of tablets by the present invention, an active material ingredient is thoroughly mixed by any suitable dry blending technique with one or more of the above-described compacted starch powders in 7 relative amounts required to provide a resultant superficially dry, freeflowing formulation directly compressible into tablets, and the fonnulation then is tabletted by direct compression.
Active ingredients contemplated to be employed in the preparation of tablets by the present invention constitute all active ingredients compatible with the above-described compacted starch powders in formulations directly compressible into tablets. The present invention is particularly adapted for use in preparing tablets containing pulverulent pharmaceuti cally active materials. Specific examples of pharmaceutically active ingredients which advantageously may be tabletted by the present invention include ascorbic acid, sodium paminosalicylate, phenacetin, and N-acetyl-p-aminophenol, all materials which heretofore generally have been tabletted only with great difficulty. The particular nature of the active material is not critical, however, and nonpharmaceutical active materials, e.g. pulverulent detergents, dyes, pesticides, and foods, forming directly compressible mixtures with the compacted starch powders can also be employed.
The amount of active material ingredient employed in preparing tablets according to the present technique depends, inter alia, upon the nature and relative compatibility of the active material, and the end use for which the tablet is desired, the latter dictating thereby the tolerable properties in terms of hardness, friability, and/or disintegratability of the final tablet. Given the minimum and preferred characteristics desired in the final tablet, the tolerable limits on the weight ratio of active ingredient to binder-disintegrant for a particular active ingredient easily may be determined by the known technique of sequentially increasing the active ingredient content of the tablet. In general, acceptable active material-containing tablets are those which display a hardness of at least about 4 kg., preferably above about 5 kg., and a friability corresponding to a weight loss of less than about l.0 percent, preferably less than about 0.5 percent. For a tablet having suitable friability, a lower hardness generally can be tolerated.
Depending upon the type and contemplated use of the final tablet, the disintegration requirements may vary over a wide range. A particular feature of the present invention is that a wide range of active ingredients may be tabletted to provide tablets displaying disintegration times in aqueous media of generally less than 30 minutes and more usually less than 15 minutes and in the range of from about 0.5 to about l0 minutes. The rapid disintegration rates of tablets prepared by the present method, as stated, stem from the advantageous characteristics of the compacted starch powders to function not only as excellent binding agents but as agents which accelerate tablet disintegration as well. ln general, specific embodiments of tablets prepared in the invention contain from about 5 to about 90 percent by weight active ingredient, dry substance basis. An additional feature of the present invention is that, by the use of the binder-disintegrant compacted starch powders, even many pulverulent active ingredients which themselves are noncompressible or only poorly compressible, exemplified by the pharmaceuticals named, may be formed into suitable tablets containing from about 20 to about 50 percent and above of the active ingredient based on the tablet dry substance weight.
Adjuvants, such as tabletting lubricants, fillers, antisticking agents, coloring agents, and the like, conventionally employed in preparing particular tablets by direct compression, suitably may be incorporated in appropriately effective amounts into the compressible formations formed in the present invention. A lubricant such as talc, magnesium stearate, or stearic acid, when employed, generally is added in an amount ranging up to about percent by weight of the total tabletting formulation. Colloidal silica constitutes a typical antisticking agent or socalled glidant." A glidant such as colloidal silica, when incorporated in a formulation, usually is added in an amount ranging up to about 2 percent of the formulation total weight. Fillers, which may also function as supplemental binders or disintegrants, where employed, must not be added in amounts which impair undesirably the direct compressibility of the tabletting formulations.
While the compacted starch powders employed in the present invention are capable of satisfying the dual requirements of a binder-disintegrant, the present invention, as stated, also contemplates embodiments wherein efiective amounts of another direct compression binder such as lactose and the like and/or a separate disintegrating agent such as native cornstarch also is incorporated into the formulation. In most cases, however, the addition of such additional binders is unimportant in view of the excellent characteristics of the binder-disintegrant compacted starch powder of this invention. in view of this, it will be understood the present invention is directed primarily to embodiments wherein the superficially dry, free-flowing binder-disintegrant starch of this invention is the major binder ingredient employed, i.e. present in an amount corresponding to at least 50 percent of the total weight amount of tablet binding agent employed, and more preferably is the sole binding agent added to the formulation for this purpose. In some instances, a supplemental disintegrant may provide some improvement. An example of this is in the preparation of tablets of sodium p-amino-salicylate dihydrate wherein the disintegration rate of the tablet advantageously may be further accelerated by the addition of a conventional granular starch disintegration aid.
The more desirable tablets are prepared from superficially dry formulations containing from about 5 to about percent moisture based on the formulation total weight. Accordingly, appropriate adjustment of the moisture content may be made, where necessary or desirable, during the formulation operation to improve the tabletting characteristics of the mixture. It may also be desirable, after mixing the ingredients, to screen the formulation to remove any oversize particles introduced in the active ingredient or tabletting aids and thereby to improve tabletting efficiency. In this respect, removal of +40 mesh particles by screening generally is desirable.
in accordance with the present invention any conventional single or rotary tablet making apparatus suitably may be employed in the tabletting operation. As is standard in conventional tabletting practice, optimum results are obtained for particular formulations by the use of the highest pressure settings consistent with good tablet press operation.
Tablets prepared from a given batch of tabletting formulation by means of the present invention are essentially uniform in thickness, weight, and active ingredient dosage level and have excellent surface smoothness as indicated by the lack of pits and cracks. A further characteristic of the tablets made according to the invention is that a substantial duplication of tablet properties is obtained by grinding the tablets to a freeflowing powder and retabletting.
While the above discussion has been limited to the preparation of tablets by direct compression, it further will be understood that the described free-flowing, directly compressible active ingredient and compacted starch powder-containing formulations, of course, also can be employed in the preparation of compressed tablets either by the double compression technique wherein slugs initially are prepared from a formulation and the slugs subsequently dry granulated to prepare tablet machine feed material or by the wet granulation method wherein a wetting agent, such as water, is added to a formulation, the moistened mass is dried without gelatinizing the compacted starch powderingredient, and the resultant dried material is ground into granular feed for the tabletting machine. Compressed tablets which can be prepared by either method have essentially the same characteristics as those produced by direct compression. In view of the adaptability of the formulations prepared hereby to direct compression tabletting, however, the dry and wet granulation methods are impractical and can be anticipated to be rarely, if ever, employed.
The invention having been described in detail, the following examples are presented to show specific embodiments thereof. It will be understood the examples are given for illustration purposes only and not by way of limitation.
EXAMPLE I This example illustrates the preparation of suitable tablet binder-disintegrant starches from an unmodified cornstarch and the use of the binder-disintegrant starches in the preparation of tablets by direct compression.
Three samples of ground hypochlorite-bleached native cornstarch (starch A) having the properties set forth in table 1 were converted to compacted starch powders by three different techniques. The techniques employed were as follows: Technique 1 (Pelletizing) One sample of the hypochlorite-bleached native cornstarch was moistened to a water content of 24-25 percent by weight and the moistened starch was pelletized at a rate of about 960 pounds/hour on a California Process Series CM-F B Master pellet mill having dies 3/16 inch in diameter and 1% inches in length and operated at about 130 r.p.m. The resultant pellets /4 inches length) were then dried in a rotary drier to 7.4 percent by weight moisture. The dried pellets were then ground to -10 mesh in a Model DS-6 Series [606 stainless steel Fitzmill grinder, and the l0 mesh material was further ground to l00 mesh in a Model PC 20 Strong-Scott Pulvocron grinder operated at 3,500 r.p.m. with the classifier at 1,000 r.p.m. and the tailings return at 100 percent. The resultant powder was remoistened to l 1.5-] 2.5 percent by weight water in a horizontal ribbon blender, and the moistened material was screened to 40 mesh. The properties of the resultant compacted starch powder (starch A,,) are set forth in table 1. Technique 2 (Differential Roll-Milling) The second sample of the ground hypochlorite-bleached native cornstarch was compacted, after being moistened to a water content of about 25.2 percent by weight, in an EEMCO Laboratory differential roll mill having l2-in. length rolls of 6 in. diameter. The mill was operated with a mill gap of l2 mils, and roll speeds of 50 and 70 linear feet/min. on the respective rolls. Roll temperature was maintained at about 23 C. by cooling water circulating through the rolls. The compacted starch sheet stripped from the rolls was then subjected to three additional passes through the mill. The resultant compact was then dried to a moisture content of 6-9 percent by weight. The dried compact was ground first to less than about 1.0 mm. in a Wiley mill and then to less than about 0.5 mm. in a Raymond hammer mill. The ground material was then remoistened with water to a moisture content of ll.8 percent by weight, and screened to mesh. The resultant compacted starch powder (starch A had the properties set forth in table I bonlike compact obtained was dried to 7 percent by weight water and then ground as in technique 2 above. The ground material was then adjusted to a moisture content of about 12.0 percent by weight, and then finally screened to 80 mesh. The properties of the resultant compacted starch powder (starch The above data indicates that the compacted starch powders are directly compressible into tablets themselves and that suitably hard, nonfriable, rapidly disintegrative tablets containing relatively high levels of heretofore difiicult-to-tablet drugs, i.e. ascorbic acid, phenacetin, and APAP, advantageously can be prepared using the compacted starch powders as sole dual-functioning binder-disintegrant ingredients. Although the NaPAS-containing tablets disintegrated relatively slowly, these tablets had suitable hardness and friability properties; the compacted starches are satisfactory binders even of this previously difficult-to-tablet drug.
EXAMPLE ll Ac) are Set forth in table in order to compare the binder-disintegrant properties of TABLE 1 Coldwater Loose Flow- H2O solu- Swellbulk ability, content, bility, ing density, angle of Starch Description percent percent; power gun/ml. repose A Hypochlorite bleached native corn starch- 10. 0 0. 2-0. 5 1. 9-2. 1 0. 52- 66 44-45 A Pelletized Starch A 12. 4 .2 6. 6 0. 57 33 ADRM Difierentlal roll-milled starch A 11.8 13. 1 6. 8 0.60 31 Ans Roll mill compacted starch A 12.0 11. 6 7. 2 0. 69 31 The data in table 1 indicates that the three different comthe compacted starch powders employed in the present invenpaction methods can each produce compacted starch powders, ssentially equivalent in these properties.
Superficially dry tabletting formulations were prepared by thoroughly blending the resultant compacted starch powders each in turn, with separate powdered preparations of ascorbic acid, phenacetin, sodium p-amino-salicylate dihydrate (NaPAS) a N-acetyl-p-aminophenol (APAP) in the proportions set forth below in table 2, incorporating talc and/or colloidal silica (Cab-o-Sil) as tabletting aids into the formulations, and screening the resultant mixtures to mesh. The 40 free-flowing powders obtained were then directly tabletted on a Colton No. 204 four-punch press manufactured by the Colton Division of Cherry-Burrell Corporation, Detroit, Mich. A set of inch diameter standard cap punches and dies was employed, and the press was operated at 35 rpm. to produce tabletted using the same tabletting procedure. The properties of the tablets obtained also are set forth in table 2.
tion with those of other compacted starches, the starting bleached native cornstarch (starch A) of example I was converted to a compacted starch powder using technique 3 of example with the exception that the moisture content of the starting starch was initially adjusted to about l8 percent by weight so that the starch was worked and modified to a lesser degree. The resultant compacted starch powder was characterized by a 2.9 percent cold-water solubles content, a swelling power of 3.0, a loose bulk density of 0.49 gm./ml., and flowability corresponding to an angle of repose of more than 40.
The resultant compacted starch powder was tabletted alone using the procedure of example I. The tablets obtained had an average hardness of 3 kg., a friability corresponding to an average weight loss of L93 percent, and a disintegration time in water of 0.5-1 .5 minutes. As evidenced by the poor flowability of the powder and the low hardness and high friability of the tablets prepared therefrom, the low cold-water solubles content powder is not suitable for use as a sole dual-functioning binder-disintegrant ingredient in preparing acceptable tablets by direct compression.
TABLE 2 Formulation composition Tablet properties Adiuvants, percent by Averageweight total formulation H20 Fria- Drug/ conbility Disintebiuder Coltent, Hardpercent gration Starch weight loidal perness, weight time,
binder Drug ratio 1 Talc silica cent kg. loss minutes Tablet Number:
1 12. 4 13. 7 0. 08 4. 5-5. 0 2 Ascorbic acid.. 7. 3 5. 9 0. 19 1. 5 3 Phenacetin.. 8. 4 5. 0 0. 44 2. 5 4 0 7. 4 5. 7 0. 23 1. 5 5 13. 3 6. 4 0. 39 -80 6 0:100 11. 8 14. 0 0. 12 6. 5-7. 0 7-. Ascorbic 150143.. 35:65 5. 0 0. 0082 7. 7 4. 5 0. 37 2. 0-2. 5 8 Phenacetin 25:75 0. 0091 9. 1 5. 4 0. 35 4. 0 9 APAP 25:75 3. 0 0. 0082 8. 4 6. 6 0. 20 2. 5-3. 0 10 :60 5 0 0.0082 13.3 5. 8 0.51 60-00 11 0:100 12. 0 14. 7 0. 1 9. 0-9. 5 12 Ascorbic acid. 30:70 5.0 0. 0092 8. 2 6. 3 0. 16 3. 0 13. A Phenacetin 30:70 0. 0091 8. 6 6. 7 0. 42 3. 0-3. 5 14 A AP 30:70 3.00 0 0093 8.4 7.2 0.43 2.0 15. NaPAS 35:65 3. 5 0 0076 12.7 6. 4 0. 31 -105 1 Based on binder dry substance weight.
EXAMPLE m This example illustrates the preparation of suitable tablet .binder-disintegrant starches from oxidized cornstarch and the use of the resultant binder-disintegrant starches in the preparation of tablets by direct compression.
Two samples of ground alkaline hypochlorite-oxidized cornstarch (starch B) were converted to compacted starch powder using techniques 2 and 3 of example 1. However, in using technique 2 the feed starch had a moisture content of 31.0 percent by weight and the roll temperature was maintained at 31 C. and in using technique 3 the feed starch had moisture content of 27.1 percent by weight, the roll gap was 0.02 in., and the force feeder speed was 5 r.p.m. The properties of the resultant compacted starch powders (starch B and starch B respectively) are set forth in table 3 below. Using the procedure of example 1, tablets were formed from each of the compacted starch powders alone and formulations prepared by thoroughly mixing each powder separately with certain drugs and tabletting aids. The compositions of the tablets and their properties are shown in table 4 below.
TABLE 3.-STARCH PROPERTIES EXAMPLE V This example illustrates the preparation of a tablet binderdisintegrant starch from a native high amylose starch and the use of the resultant binder-disintegrant starch in preparing tablets.
The procedure of technique 2 (difierential roll-milling) of example 1 was employed to convert a native high amylose starch (commonly known as Amylomaize" and designated starch D) to a compacted starch powder except that a starch feed moisture content of 27.6 percent by weight and roll tem- H1O Cold Flowconwater Loose ability,
tent, solu- Swellbulk angle perbilit ing density, of
Example N 0. Starch Description cent percent power gm./m1. repose B Oxidized corn starch 11. 3 1. 3 2. 1
III B RM Differential roll-milled starch B. 11. 7 10. 2 3. 6 34 B50 12.3 33.6 7.1 27
Iv Native corn star 11. 1 0. 3 1. 9 36 C Differential roll-min ch 0 11. 9 6. 9 4. 8 28 V D Native high amylose starch 10. 9 0. 4 2. 6 29 DDRM Difierential roll-milled starch D 11. 9 4. 0 3. 9 31 VI {E Acid-modified corn starch..... 10. 9 1. 1 2. 3 38 Em Difierential roll-milled starch E 12.0 17.7 4.0 31 VII F Derivatized corn starch 10. 9 0. 8 2. 1 45 Fmm Difierential roll-milled starch F. 12. 1 31. 6. 5 34 VH1 G Gr0ss-linked starch 10. 7 1. 9 2. 3 28 GDR Differential roll-milled starch G-.. 11. 9 21. l 7. 0 29 IX H Native potato starch 13. 9 0. 6 2. 2 31 H Differential roll-milled starch H.-. 12. 1 21. 0 2. 5 32 EXAMPLE IV This example illustrates the preparation of a suitable tablet binder-disintegrant starch from native cornstarch and the use 45 of the resultant binder-disintegrant starch in making tablets.
Native cornstarch (starch C) was converted to a compacted perature of 10 C. were used. The properties of the starting starch and resultant compacted starch powder (starch D are set forth in table 3. The properties of placebo and drugcontaining tablets prepared using the compacted starch powder in the general tabletting procedure of example I are shown in table 4.
TABLE 4 Formulation composition Tablet properties Percent by weight total Averageadjuvants,
formula H Fria- Drug conbilit Disinteblnder Coltent, Hardpercent gration Tablet Starch wel ht loidal perpass, weight time, Example No. binder Drug rat 0 l Talc silica cent kg loss minute 18 B R 0: 100 11. 7 14. 0 0.12 6. 5-7. 0 19 Bonn Phenacetin. :60 0.0103 7. 4 5. 4 0. 43 3. 5 20 Bmuvr Ascorbic acid- 7. 0 5. 0 0. 16 3. 0 III 21 Bmm NaPAS 12. 8 B. 4 0. 34 45-60 22 BnnM APAP 7. 7 7. 8 0. l8 3. 5-4. 0 23 B110 12. 3 10.8 0.09 15. 0 24 B10 Phenacetin. 8. 3 4. 6 0. 41 5. 0-6. 0 25 CDB 11.9 14. 3 0. 10 5.0-6. 5 26 Conzvr Phenacetin- 7. 7 7. 7 0. 38 3.0-4. 0 IV 27 0mm Ascorbic acid- 7. 1 6. 0 0. 31 5. 5-6. 0 28 CDRM N aPAS 13. 3 6. 7 0. 28 70-80 29 Goa-M APAP 7. 7 8. 4 0. 14 3. 5-4. 0 30 Dun 11. 9 13. 3 0. 05 3. 5-4. 0 31 DDnM Phenacetin- 7. 9 7. 1 0. 34 2. 5 32 Dmuvr Ascorbic acid. 6. 4 5. 4 0.31 3. 0-3. 5 33 DDRM N PAS 13. 3 7. 5 0. 28 75-85 34 DDRM 7. 7 7. 7 0. 26 2. 0-2. 5 35 Epmvr 12. 0 9. 5 0. 11 4. 0 36 Fnmu 12. 1 9. 8 0. 05 9. 5-10. 5 37 GrmM 11. 9 9. 5 0. ll 4. 0 38 Harm 12. 1 10. 1 0. 12 29. 0
1 Based on binder dry substance weight.
This example illustrates the preparation and use of a tablet binder-disintegrant starch derived from an acid-modified starch raw material.
An acid-modified starch (starch E) having an alkali fluidity of about 62 cc. g. starch, as is basis, 77 F. and 0.375 N sodium hydroxide) was converted to a compacted starch powder employing technique 2 (differential roll-milling) of example I except that the starch feed moisture content utilized was 28.0-30.5 by weight, the roll gap was 6'mils, and the roll temperature was maintained at 23-26 C. A comparison of the properties of the starting granular starch and the resultant compacted starch powder (starch E obtained are set forth in table 3. Following the tabletting procedure of example I, placebo tablets (without drugs) were prepared using the compacted starch powder alone. The properties of the tablets obtained are reflected in table 4.
The results of these tests indicate the resultant compacted starch powder is a suitable binder-disintegrant ingredient for use in preparing acceptable drug-containing tablets by direct compression as in the previous examples.
EXAMPLE Vll This example illustrates the preparation an use of a tablet binder-disintegrant starch obtained from a derivatized granular starch raw material.
A granular derivatized cornstarch containing about 2.5 percent acetyl groups (starch F) was converted to a compacted starch powder using technique 2 (differential roll-milling) of example 1 except that the feed starch moisture content was 28.3-3l percent by weight, a roll gap of 12 mils was employed, and roll temperatures were maintained at 23-24 C. The properties of the starting starch and the resultant compacted starch powder (starch F are set forth in table 3. Using the tabletting procedure of example I, placebo (drugfree) tablets were prepared from the compacted starch powders. The properties of the tablets are shown in table 4.
When substituted as the binder-disintegrant ingredient in the preparation of the drug-containing tablets described in the preceding examples, the compacted starch powder provides tablets of properties comparable to those mentioned.
EXAMPLE Vlll This example illustrates the preparation and use of a tablet binder-disintegrant starch obtained from a cross-linked granular starch raw material.
The procedure of example VI was repeated with the exception of substituting a granular cross-linked cornstarch obtained by reacting oxidized cornstarch with phosphorus oxychloride (starch G) for the acid-modified starch. The properties of the starting starch and resultant compacted starch powder (starch G are set forth in table 3. The characteristics of the tablets obtained are shown in table 4. Drugcontaining tablets prepared by direct compression, using the resultant compacted starch powder as a binder-disintegrant ingredient as in the preceding examples, have characteristics similar to such tablets described above.
EXAMPLE IX This example illustrates the preparation and utilization of a tablet binder-disintegrant starch derived from potato starch.
The procedure of example Vll was repeated except that native potato starch (starch H) was substituted for the derivatized cornstarch. A comparison of the properties of the starting starch and the resultant compacted starch powder (starch H is shown in table 3, and the characteristics of the placebo tablets prepared therefrom are listed in table 4. When employed as a binder-disintegrant ingredient in preparing drug-containing compressed tablets, such as those prepared above by direct compression, the resultant compacted starch powder provides acceptable tablets.
EXAMPLE x This example illustrates an embodiment of the present invention wherein a binder-disintegrant starch is employed in combination with an uncompacted starch in the preparation of active ingredient tablets by direct compression, the uncompacted starch being employed as a filler and disintegrant ingredient in the tablets.
A sample of starch D (differential roll-milled native cornstarch) described above in example iv was thoroughly mixed with sodium p-aminosalicylate dihydrate (NaPAS) and ground bleached native cornstarch containing about 10 percent by weight moisture in a weight ratio of drug:compacted starchzuncompacted starch of 30:60:10, starch dry substance basis. Talc and colloidal silica (Cab-o-Sil) also were added during the mixing in amounts of 6.0 percent and 0.0l09 percent by weight of the total fonnulation, respectively. The resultant powder which had a moisture content of 12.1 percent by weight was tabletted directly using the procedure of example I. The resultant tablets were characterized by an average hardness of 8.7 kg., a friability corresponding to an average weight loss of 0.24 percent, and a disintegration time of 20-26 minutes.
EXAMPLE Xl This example illustrates embodiments of the present invention wherein a binder-disintegrant starch is employed in the preparation of tablets by direct compression wherein the tablets are intended for nonpharmaceutical uses.
Using starch A, (pelletized bleached native cornstarch) described in example I as the binder-disintegrant ingredient and the tabletting procedure of example 1, tablets that disintegrate rapidly in water and have excellent hardness and friability properties are prepared from the following formulations:
Plant Root-growth Stimulant Tablets Parts by weight Starch A,
l-Naphthalene acetic acid 9 Colloidal silica (Cab-o-Sil) 1 Garlic Tablets Starch A, 23
Powdered garlic (Dehydrated) 7U Colloidal silica (Cah-n-Sil) 2 Table 5 below contains comparative data showing that compaction of starch so as to impart the properties set forth above in table form on page 7 renders the starch powder useful in forming tablets by direct compression whereas the same starch, noncompacted, does not have this property. In the table the heading Allis-Chalmers Compacter Conditions" refers to technique 3 set forth on page 22 above while the heading Differential Roll Mill Conditons refers to technique 2 set forth above on pages 21 and 22. The starch used in samples Nos. 1-10, 12 and 13 is ordinary powder native cornstarch bleached with sodium hypochlorite to make it whiter while the oxidized starch used in sample 1 l is a corn starch oxidized by sodium hypochlorite under alkaline conditions until it has about 0.5 percent carboxyl groups.
The data in table 5 may be summarized as follows:
a. Sample 1, 2, 7, 8, 9 and 10, which were not compacted and which did not fall within the parameters set forth on page 7 with respect to at least two of cold-water solubility, swelling power, loose bulk density, and moisture content, could not be tabletted.
b. Samples 3, 4, 5, 6, ll, l2 and I3, which were compacted, could be tabletted. However, sample 3 had a cold-water solubility below the required minimum and the tablets formed therefrom were not satisfactory since they were not suffrciently hard and were excessively friable. Samples 4, 5 and 6 had values for cold-water solubility, loose bulk density and swelling power within the range as set forth in the table on page 7.
c. Sample 13, which was compacted well beyond any of the others, had excess cold-water solubility and excess swelling cent of said powder is -80 mesh size, at least about percent of said powder is +270 mesh size, and from about to about 90 percent of said powder is -270 mesh size said powder being adapted to function as the essential, bifunctional disinower. While it could be tabletted, the bl t did not di i 5 tegrant and binder in the direct compression method of tablet tegrate in over minutes, well beyond the requirements for a ma yf q m useful tablet binder-disintegrant. 2. The compressed tablet according to claim 1 wherein said d. In the Allis-Chalmers Compacter, increasing compaction active ingredient is a pharmaceutically active compound. is obtained by narrowing the gap, increasing the water con- 3. The compressed tablet according to claim I wherein said tent, increasing the speed of the feeder, increasing the bearing 10 active ingredient is a nonphannaceutically active conmound. pressure or any combination of these. The data for samples 3, 4. The compressed tablet according to claim 1 wherein said 4, 5 and 6 show that increasing the extent of compaction incompacted starch powder constitutes at least about percreased the tablet hardness and disintegration time while cent of the total weight amount of binder in said tablet. decreasing friability. 5. The compressed tablet according to claim 1 wherein the TABLE 5- Allis Chalmers eompacter Powder subjected to tabletting conditions 80 mesh) Tablet H10 Bearing Percent Loose Friabllity in Roll Force prescold bulk Swell- Per- Hardpercent Disintefeed gap, feeder, sure, water density ing cent ness weight gratlon, Type of starch starch inches r.p.m lbs. solubles gm./ml. power H1O (kg.) loss minutes Sample Number:
i313"'""""ijfifiiiiif'iiiifIi: $819 ::133::::::::::::::::::::::::: 333 3:25 2. 1? 32? Unable to make tablets 18.2 2. 0 0. 49 2. 97 11. 0 3.0 1. 93 0. 5-1. 5 18. 2 7.4 0. 50 5.02 11.9 7.3 0. 32 5.0-5. 5 21.6 11. 6 0.59 7.17 11.9 14. 7 0.10 9.0-9.5 21.6 13. 3 0. 9. 04 11.9 12.2 0. 05 18.0-19.5 11.6 0.4 0.51 2.01 11.6 13:1 8:3 8: i3 '1??? 13:1 Unable to make tables Difierential roll mill conditions Roll Rgsll Noi gap spee o mils fin/min: passes 11 Oxidized starch- 31. 0 12 50-70 2 10. 2 0. 56 3. 64 11. 7 14. 0 0. l2 6. 5-7. 0 12.. 25. 2 12 50-70 4 13. 1 0. 6. 79 11. 8 13. 2 0. 13 7. 5-8. 5 13 27.0 12 50-70 4 61.1 0. 56 12. 3 11.8 14. s 0. 01 2 4 1 Minutes eqsulvalent to 128 to 180 passes. 2 Had not d integrated in 45 minutes when test was halted.
We claim:
1. A directly compressed tablet requiring a disintegrant and a binder, having resistance to breaking and crumbling, and being capable of disintegrating in an a ueous medium, said tablet comprising (a) an active ingredten by which said tablet derives its utility and (b) a pulverulent cohesive binder for said active ingredient, said binder comprising as the only dualfunction binder and tablet-disintegrant a directly compressible compacted starch powder in a concentration that provides substantial binding action and substantially accelerates disintegration of said tablet in an aqueous medium, said compacted starch powder being a superficially dry, free-flowing material in which the starch is in the form of a mixture of birefringent granules and nonbirefringent fragments of granules, in which some aggregates of granules and fragments are present and having a cold-water solubility in the range of from about 4 to about 40 percent by weight, dry substance basis, a swelling power in the range of from about 2.5 to about l2, a loose bulk density in the range of from about 0.50 to about 0.70 gram per milliliter, a moisture content in the range of from about 9 to about 16 percent, total weight basis, and a particle size distribution such that said powder is essentially free of +40 mesh size material and that on a total weight basis, at least 90 peramount of said active ingredient in said tablet is in the range of from about 5 percent to about percent dry substance weight basis.
6. The compressed tablet according to claim 1 wherein said compacted starch powder constitutes at least about 50 percent of the total weight amount of binder in said tablet, has a cold-water solubility in the range of from about 6 to about 20 percent, dry substance weight basis, and a swelling power in the range of from about 3.5 to about 10, and contains, on a total weight basis, from about 45 to about 75 percent of material which is -270 mesh.
7. The compressed tablet according to claim 6 wherein said compacted starch is a compacted granular cornstarch raw material.
8. The compressed tablet according to claim 7 wherein said granular cornstarch raw material is bleached native cornstarch and said compacted starch powder has a cold-water solubility in the range of from about 6 to about 15 percent, dry substance weight basis, and a swelling power in the range of from about 5 to about 8.
i i Q i i UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,622,677 Dated November 23, 1971 Inventor(s) Rolland W. P. Short and Frank Verbanac It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 3, line 41, "powers" should be --powders--.
Column 9, line 17, "formations" should be --formula.tions-.
Column 11, line 36, "a" should be -a.nd--.
Column ll, Table 2, last column, next to last entry reading as "2.0 should be --2.5-- and last entry reading as "90-105" should be --90-lOO--.
Column 13, Table 3, third column, line 5, "roll-minded" should be -rollmilled-.
Column 15, line 7, should be --gm.--
Column 15, line 26, "an" should be --a.nd-.
Column 16, line 57, "Conditons" should be "Conditions".
Signed and sealed this 9th day of January 1973.
(SEAL) Attest:
EDWARD M.FLETCHER,JR. ROBERT GOTTSCHALK Attesting Officer Commissioner of Patents

Claims (7)

  1. 2. The compressed tablet according to claim 1 wherein said active ingredient is a pharmaceutically active compound.
  2. 3. The compressed tablet according to claim 1 wherein said active ingredient is a nonpharmaceutically active compound.
  3. 4. The compressed tablet according to claim 1 wherein said compacted starch powder constitutes at least about 50 percent of the total weight amount of binder in said tablet.
  4. 5. The compressed tablet according to claim 1 wherein the amount of said active ingredient in said tablet is in the range of from about 5 percent to about 90 percent dry substance weight basis.
  5. 6. The compressed tablet according to claim 1 wherein said compacted starch powder constitutes at least about 50 percent of the total weight amount of binder in said tablet, has a cold-water solubility in the range of from about 6 to about 20 percent, dry substance weight basis, and a swelling power in the range of from about 3.5 to about 10, and contains, on a total weight basis, from about 45 to about 75 percent of material which is -270 mesh.
  6. 7. The compressed tablet according to claim 6 wherein said compacted starch is a compacted granular cornstarch raw material.
  7. 8. The compressed tablet according to claim 7 wherein said granular cornstarch raw material is bleached native cornstarch and said compacted starch powder has a cold-water solubility in the range of from about 6 to about 15 percent, dry substance weight basis, and a swelling power in the range of from about 5 to about 8.
US839590A 1969-07-07 1969-07-07 Compressed tablets containing compacted starch as binder-disintegrant ingredient Expired - Lifetime US3622677A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83959069A 1969-07-07 1969-07-07

Publications (1)

Publication Number Publication Date
US3622677A true US3622677A (en) 1971-11-23

Family

ID=25280152

Family Applications (1)

Application Number Title Priority Date Filing Date
US839590A Expired - Lifetime US3622677A (en) 1969-07-07 1969-07-07 Compressed tablets containing compacted starch as binder-disintegrant ingredient

Country Status (1)

Country Link
US (1) US3622677A (en)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4013775A (en) * 1968-10-14 1977-03-22 Cpc International Inc. Process for preparing a sugar tablet
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4143129A (en) * 1975-10-11 1979-03-06 Lilly Industries Limited Cephalexin tablets
US4159346A (en) * 1976-09-07 1979-06-26 Fmc Corporation Tablet compositions
US4209513A (en) * 1974-02-14 1980-06-24 Burroughs Wellcome Co. Tablet formulation
US4272295A (en) * 1978-06-20 1981-06-09 N. B. Love Industries Pty. Ltd. Starch-based adhesives
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4383111A (en) * 1980-06-12 1983-05-10 Asahi Kasei Kogyo Kabushiki Kaisha Processed starch, process for preparing same and use of same in medicines
US4454108A (en) * 1981-09-04 1984-06-12 Chugai Seiyaku Kabushiki Kaisha Prolonged-action multiple-layer tablets
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4495177A (en) * 1983-01-17 1985-01-22 Shaklee Corporation Gel tableting agent
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
EP0159631A2 (en) * 1984-04-23 1985-10-30 National Starch and Chemical Corporation Compressible starches as binders for tablets or capsules
US4601895A (en) * 1983-12-23 1986-07-22 Bayer Aktiengesellschaft Delayed-action acetylsalicylic acid formulations for oral administration
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US4725387A (en) * 1981-02-12 1988-02-16 Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo Process of shaping anhydrous crystals of maltitol and the whole crystalline hydrogenated starch hydrolysate mixture solid containing the crystals
US4954178A (en) * 1987-01-05 1990-09-04 Penford Products Co. Starch hydrolyzate product
WO1992016108A1 (en) * 1991-03-25 1992-10-01 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
WO1992016107A1 (en) * 1991-03-25 1992-10-01 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
US5164014A (en) * 1989-05-16 1992-11-17 Societe D'exploitation De Produits Pour Les Industries Chimiques S.E.P.P.I.C. Process for the manufacture of a directly compressible starch for use in the manufacture of tablets, and tablets obtained
WO1994021236A1 (en) * 1993-03-25 1994-09-29 Labopharm Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
US5456921A (en) * 1990-11-27 1995-10-10 Labopharm, Inc. Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5667803A (en) * 1994-06-07 1997-09-16 Oy Polymer Corex Kuopio Ltd. Starch acetate composition with modifiable properties, method for preparation and usage thereof
US5747068A (en) * 1994-07-20 1998-05-05 Lilly S. A. Flouxetine pharmaceutical formulations
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5830884A (en) * 1995-01-18 1998-11-03 National Starch And Chemical Investment Holding Corporation Pharmaceutical products containing thermally-inhibited starches
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5883045A (en) * 1994-03-04 1999-03-16 Nihon Bayer Agrochem K.K. Method for the treatment of plants with agrochemical tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5989589A (en) * 1997-10-24 1999-11-23 Cartilier; Louis Cross-linked cellulose as a tablet excipient
US6001408A (en) * 1995-10-13 1999-12-14 Corn Products International, Inc. Starch products having hot or cold water dispersibility and hot or cold swelling viscosity
US6051252A (en) * 1997-12-22 2000-04-18 Schering Corporation Orally administrable solid dosage form
US6143324A (en) * 1998-02-03 2000-11-07 Cerestar Holdings B.V. Free-flowable directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
US6207189B1 (en) * 1999-08-10 2001-03-27 Aboca Di Mercati Valentino & C. Societa Semplice Procedure for the production of capsules and tablets of natural substances of vegetable origin
US20020090367A1 (en) * 1997-10-31 2002-07-11 Vincent Fischetti Therapeutic treatment of upper respiratory infections
US20020119133A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating various illnesses
US20020127206A1 (en) * 1999-09-14 2002-09-12 Vincent Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6455069B1 (en) 1999-06-26 2002-09-24 Cerestar Holding B.V. Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US6506720B1 (en) * 1997-03-13 2003-01-14 Henkel Kommanditgesellschaft Auf Aktien Process for preparing household detergent or cleaner shapes
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6572887B2 (en) 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US20030117171A1 (en) * 2001-12-20 2003-06-26 Fujitsu Limited Input/output buffer circuit
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6617446B1 (en) 1999-06-03 2003-09-09 National Starch And Chemical Investment Holding Corporation Cold water swellable starches exhibiting delayed viscosity development, preparation and use thereof
US20030215561A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Resistant starch prepared by isoamylase debranching of low amylose starch
US20030215499A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Use of completely linear short chain alpha-glucans as a pharmaceutical excipient
US20030215562A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Slowly digestible starch product
US20030219520A1 (en) * 2002-05-14 2003-11-27 Yong-Cheng Shi Slowly digestible starch product
US6685937B2 (en) 1997-10-31 2004-02-03 New Horizons Diagnostics Corp. Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
US20040069300A1 (en) * 2000-06-23 2004-04-15 Francesco Roversi Use of an acetylated pre-gelled starch with a high content of amylose
US20040076624A1 (en) * 1997-10-31 2004-04-22 Vincent Fischetti Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
US6733749B2 (en) 1997-10-31 2004-05-11 New Horizons Diagnostics Corporation Throat lozenges for the treatment of Hemosphilus influenza
US20040091470A1 (en) * 2000-11-02 2004-05-13 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
US6846497B2 (en) 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
US6893589B1 (en) * 1999-01-22 2005-05-17 Agform Limited Process for producing granules
US20060008521A1 (en) * 2004-07-09 2006-01-12 Yeli Zhang Tablet excipient
US7008912B1 (en) 1997-03-11 2006-03-07 Henkel Kgaa Pressed piece which disintegrates in liquids
US7186293B2 (en) 2005-03-23 2007-03-06 Bpsi Holdings, Inc. Agglomerated starch compositions
US20070054027A1 (en) * 2005-09-08 2007-03-08 Eric Weisser Starch hydrolysis products for size enlargement
US20070077295A1 (en) * 2005-06-13 2007-04-05 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
WO2008032767A1 (en) * 2006-09-14 2008-03-20 Astellas Pharma Inc. Orally disintegrating tablet and process for production thereof
US20090011014A1 (en) * 2004-12-24 2009-01-08 Universite De Montreal Tablet Formulation for Sustained Drug-Release
US20090036408A1 (en) * 2003-01-14 2009-02-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP2034953A2 (en) * 2006-06-26 2009-03-18 Capricorn Pharma, Inc. Orally disintegrating layered compositions
WO2009123102A1 (en) 2008-03-31 2009-10-08 旭化成ケミカルズ株式会社 Processed starch powder with excellent disintegration properties and manufacturing method thereof
US20100015225A1 (en) * 2006-12-22 2010-01-21 Anke Diederich Solid dispersion of a neurokinin antagonist
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US7687069B2 (en) 1997-10-31 2010-03-30 Vincent Fischetti Time release patch containing phage associated lytic enzymes for treating bacterial infections of the skin
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20110124777A1 (en) * 2001-10-23 2011-05-26 Innogel Ag Polysaccharide based network and method for the production thereof
US20110217342A1 (en) * 2000-04-12 2011-09-08 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US20130266955A1 (en) * 2010-12-31 2013-10-10 Wensheng Xia Effervescent compositions and uses thereof
US8598185B2 (en) 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US20150065451A1 (en) * 2012-03-28 2015-03-05 The Research Foundation Of State University Of New York Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
EP2773225B1 (en) 2011-11-04 2016-11-30 Unilever N.V. Shaped food concentrate
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US11160825B2 (en) 2013-09-19 2021-11-02 Research Foundation Of The State University Of New York Methods and materials for treating diabetes or liver steatosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3101299A (en) * 1960-11-17 1963-08-20 Parisienne D Expansion Chimiqu Silica-gel powder tablet compositions
US3424842A (en) * 1964-05-09 1969-01-28 Merck Ag E Manufacture of tablets directly from dry powders
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3490742A (en) * 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3101299A (en) * 1960-11-17 1963-08-20 Parisienne D Expansion Chimiqu Silica-gel powder tablet compositions
US3424842A (en) * 1964-05-09 1969-01-28 Merck Ag E Manufacture of tablets directly from dry powders
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3490742A (en) * 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets

Cited By (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013775A (en) * 1968-10-14 1977-03-22 Cpc International Inc. Process for preparing a sugar tablet
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4209513A (en) * 1974-02-14 1980-06-24 Burroughs Wellcome Co. Tablet formulation
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4143129A (en) * 1975-10-11 1979-03-06 Lilly Industries Limited Cephalexin tablets
US4159346A (en) * 1976-09-07 1979-06-26 Fmc Corporation Tablet compositions
US4272295A (en) * 1978-06-20 1981-06-09 N. B. Love Industries Pty. Ltd. Starch-based adhesives
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4383111A (en) * 1980-06-12 1983-05-10 Asahi Kasei Kogyo Kabushiki Kaisha Processed starch, process for preparing same and use of same in medicines
US4447601A (en) * 1980-06-12 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Processed starch, process for preparing same and use of same in medicines
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4725387A (en) * 1981-02-12 1988-02-16 Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo Process of shaping anhydrous crystals of maltitol and the whole crystalline hydrogenated starch hydrolysate mixture solid containing the crystals
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4454108A (en) * 1981-09-04 1984-06-12 Chugai Seiyaku Kabushiki Kaisha Prolonged-action multiple-layer tablets
US4495177A (en) * 1983-01-17 1985-01-22 Shaklee Corporation Gel tableting agent
US4601895A (en) * 1983-12-23 1986-07-22 Bayer Aktiengesellschaft Delayed-action acetylsalicylic acid formulations for oral administration
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
EP0159631B1 (en) * 1984-04-23 1990-02-07 National Starch and Chemical Corporation Compressible starches as binders for tablets or capsules
EP0159631A2 (en) * 1984-04-23 1985-10-30 National Starch and Chemical Corporation Compressible starches as binders for tablets or capsules
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US4954178A (en) * 1987-01-05 1990-09-04 Penford Products Co. Starch hydrolyzate product
US5164014A (en) * 1989-05-16 1992-11-17 Societe D'exploitation De Produits Pour Les Industries Chimiques S.E.P.P.I.C. Process for the manufacture of a directly compressible starch for use in the manufacture of tablets, and tablets obtained
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
US5456921A (en) * 1990-11-27 1995-10-10 Labopharm, Inc. Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
WO1992016107A1 (en) * 1991-03-25 1992-10-01 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
US5369100A (en) * 1991-03-25 1994-11-29 Valent U.S.A. Corporation Chemically stable compacted particles containing insecticidal phosphoroamidothioates and methods for the manufacture and use thereof
US5352674A (en) * 1991-03-25 1994-10-04 Valent U.S.A. Chemically stable granules containing insecticidal phosphoroamidothioates
US5298501A (en) * 1991-03-25 1994-03-29 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
WO1992016108A1 (en) * 1991-03-25 1992-10-01 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
WO1994021236A1 (en) * 1993-03-25 1994-09-29 Labopharm Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
US5883045A (en) * 1994-03-04 1999-03-16 Nihon Bayer Agrochem K.K. Method for the treatment of plants with agrochemical tablet compositions
US5667803A (en) * 1994-06-07 1997-09-16 Oy Polymer Corex Kuopio Ltd. Starch acetate composition with modifiable properties, method for preparation and usage thereof
US5747068A (en) * 1994-07-20 1998-05-05 Lilly S. A. Flouxetine pharmaceutical formulations
US5830884A (en) * 1995-01-18 1998-11-03 National Starch And Chemical Investment Holding Corporation Pharmaceutical products containing thermally-inhibited starches
US6001408A (en) * 1995-10-13 1999-12-14 Corn Products International, Inc. Starch products having hot or cold water dispersibility and hot or cold swelling viscosity
US6410075B1 (en) 1995-10-13 2002-06-25 Corn Products International, Inc. Starch products having hot or cold water dispersibility and hot or cold swelling viscosity
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US7008912B1 (en) 1997-03-11 2006-03-07 Henkel Kgaa Pressed piece which disintegrates in liquids
USRE39139E1 (en) * 1997-03-13 2006-06-20 Henkel Kgaa Process for preparing household detergent or cleaner shapes
US6506720B1 (en) * 1997-03-13 2003-01-14 Henkel Kommanditgesellschaft Auf Aktien Process for preparing household detergent or cleaner shapes
US5989589A (en) * 1997-10-24 1999-11-23 Cartilier; Louis Cross-linked cellulose as a tablet excipient
US20040076624A1 (en) * 1997-10-31 2004-04-22 Vincent Fischetti Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
US6899874B2 (en) 1997-10-31 2005-05-31 New Horizons Diagnostics Corporation Method for the treatment of bacterial vaginal infections
US20020090367A1 (en) * 1997-10-31 2002-07-11 Vincent Fischetti Therapeutic treatment of upper respiratory infections
US20020119131A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses
US20020119133A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating various illnesses
US20020119134A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating various illnesses
US7141241B2 (en) 1997-10-31 2006-11-28 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses
US20020127220A1 (en) * 1997-10-31 2002-09-12 Vincent Fiochetti Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract-
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US20020146403A1 (en) * 1997-10-31 2002-10-10 Vincent Fischetti Method for the treatment of bacterial eye infections
US20020159987A1 (en) * 1997-10-31 2002-10-31 Vincent Fischetti Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US7014850B2 (en) 1997-10-31 2006-03-21 New Horizons Diagnostics Corp Nasal spray for treating streptococcal infections
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US7687069B2 (en) 1997-10-31 2010-03-30 Vincent Fischetti Time release patch containing phage associated lytic enzymes for treating bacterial infections of the skin
US6936244B2 (en) 1997-10-31 2005-08-30 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6893635B2 (en) 1997-10-31 2005-05-17 New Horizons Diagnostics Corp Therapeutic treatment of upper respiratory infections using a nasal spray
US6881403B2 (en) 1997-10-31 2005-04-19 New Horizons Diagnostic, Corp Tampon for the treatment of Streptococcus Group B infections of the vagina
US6875431B2 (en) 1997-10-31 2005-04-05 New Horizons Diagnostics Corp. Method for the treatment of bacterial eye infections
US6737079B2 (en) 1997-10-31 2004-05-18 New Horizons Diagnostics Corporation Bandage composition containing a phage associated lytic enzyme
US6733749B2 (en) 1997-10-31 2004-05-11 New Horizons Diagnostics Corporation Throat lozenges for the treatment of Hemosphilus influenza
US7169408B2 (en) 1997-10-31 2007-01-30 New Horizons Diagnostics Corp. Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
US6685937B2 (en) 1997-10-31 2004-02-03 New Horizons Diagnostics Corp. Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6051252A (en) * 1997-12-22 2000-04-18 Schering Corporation Orally administrable solid dosage form
US6143324A (en) * 1998-02-03 2000-11-07 Cerestar Holdings B.V. Free-flowable directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
US6893589B1 (en) * 1999-01-22 2005-05-17 Agform Limited Process for producing granules
US20050187109A1 (en) * 1999-01-22 2005-08-25 Agform Limited Process for producing granules
US6617446B1 (en) 1999-06-03 2003-09-09 National Starch And Chemical Investment Holding Corporation Cold water swellable starches exhibiting delayed viscosity development, preparation and use thereof
US6455069B1 (en) 1999-06-26 2002-09-24 Cerestar Holding B.V. Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets
US6207189B1 (en) * 1999-08-10 2001-03-27 Aboca Di Mercati Valentino & C. Societa Semplice Procedure for the production of capsules and tablets of natural substances of vegetable origin
US20020127206A1 (en) * 1999-09-14 2002-09-12 Vincent Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US7063837B2 (en) 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US20110217342A1 (en) * 2000-04-12 2011-09-08 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US9358207B2 (en) * 2000-04-12 2016-06-07 Otsuka Pharmaceutical Co., Ltd. Flashmelt oral dosage formulation
US20130296337A1 (en) * 2000-04-12 2013-11-07 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US8518421B2 (en) * 2000-04-12 2013-08-27 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US20050136088A1 (en) * 2000-04-28 2005-06-23 New Horizons Diagnostics Corporation Use of bacterial phage associated lysing enzymes for treating various illnesses
US6572887B2 (en) 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US20040069300A1 (en) * 2000-06-23 2004-04-15 Francesco Roversi Use of an acetylated pre-gelled starch with a high content of amylose
US7056377B2 (en) * 2000-06-23 2006-06-06 F.T. Holdings S.A. Use of an acetylated pre-gelled starch with a high content of amylose
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US20040091470A1 (en) * 2000-11-02 2004-05-13 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
US20110124777A1 (en) * 2001-10-23 2011-05-26 Innogel Ag Polysaccharide based network and method for the production thereof
US8153783B2 (en) 2001-10-23 2012-04-10 Innogel Ag Polysaccharide based network and method for the production thereof
US20030117171A1 (en) * 2001-12-20 2003-06-26 Fujitsu Limited Input/output buffer circuit
US20030215561A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Resistant starch prepared by isoamylase debranching of low amylose starch
US20030215562A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Slowly digestible starch product
US6890571B2 (en) 2002-05-14 2005-05-10 National Starch And Chemical Investment Holding Corporation Slowly digestible starch product
US6929817B2 (en) 2002-05-14 2005-08-16 National Starch & Chemical Investment Holding Corporation Slowly digestible starch product
US7081261B2 (en) 2002-05-14 2006-07-25 National Starch And Chemical Investment Holding Corporation Resistant starch prepared by isoamylase debranching of low amylose starch
US20030215499A1 (en) * 2002-05-14 2003-11-20 Yong-Cheng Shi Use of completely linear short chain alpha-glucans as a pharmaceutical excipient
US20030219520A1 (en) * 2002-05-14 2003-11-27 Yong-Cheng Shi Slowly digestible starch product
US20090036408A1 (en) * 2003-01-14 2009-02-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8716264B2 (en) 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8592397B2 (en) 2003-01-14 2013-11-26 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9744181B2 (en) 2003-01-14 2017-08-29 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US6846497B2 (en) 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
US8871270B2 (en) 2004-07-09 2014-10-28 Corn Products Development, Inc Tablet excipient
US20060008521A1 (en) * 2004-07-09 2006-01-12 Yeli Zhang Tablet excipient
US20090011014A1 (en) * 2004-12-24 2009-01-08 Universite De Montreal Tablet Formulation for Sustained Drug-Release
JP2008534498A (en) * 2005-03-23 2008-08-28 ビーピーエスアイ ホールディングス,エルエルシー. Agglomerated starch composition
US7186293B2 (en) 2005-03-23 2007-03-06 Bpsi Holdings, Inc. Agglomerated starch compositions
US9018192B2 (en) 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US20070077295A1 (en) * 2005-06-13 2007-04-05 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US9545414B2 (en) 2005-06-13 2017-01-17 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US8598185B2 (en) 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US20070054027A1 (en) * 2005-09-08 2007-03-08 Eric Weisser Starch hydrolysis products for size enlargement
EP2034953A2 (en) * 2006-06-26 2009-03-18 Capricorn Pharma, Inc. Orally disintegrating layered compositions
EP2034953A4 (en) * 2006-06-26 2013-05-15 Capricorn Pharma Inc Orally disintegrating layered compositions
WO2008032767A1 (en) * 2006-09-14 2008-03-20 Astellas Pharma Inc. Orally disintegrating tablet and process for production thereof
JP5332615B2 (en) * 2006-09-14 2013-11-06 アステラス製薬株式会社 Orally disintegrating tablet and method for producing the same
US20080085309A1 (en) * 2006-09-14 2008-04-10 Astellas Pharma Inc. Rapidly disintegrating tablets in buccal cavity and manufacturing method thereof
US20100015225A1 (en) * 2006-12-22 2010-01-21 Anke Diederich Solid dispersion of a neurokinin antagonist
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
WO2009123102A1 (en) 2008-03-31 2009-10-08 旭化成ケミカルズ株式会社 Processed starch powder with excellent disintegration properties and manufacturing method thereof
US8431618B2 (en) 2008-03-31 2013-04-30 Asahi Kasei Chemicals Corporation Processed starch powder with excellent disintegration properties and manufacturing method thereof
US9243279B2 (en) * 2010-12-31 2016-01-26 3M Innovative Properties Company Effervescent compositions and uses thereof
US20130266955A1 (en) * 2010-12-31 2013-10-10 Wensheng Xia Effervescent compositions and uses thereof
US10378041B2 (en) 2010-12-31 2019-08-13 3M Innovative Properties Company Effervescent compositions and uses thereof
EP2773225B1 (en) 2011-11-04 2016-11-30 Unilever N.V. Shaped food concentrate
US20150065451A1 (en) * 2012-03-28 2015-03-05 The Research Foundation Of State University Of New York Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
US11160825B2 (en) 2013-09-19 2021-11-02 Research Foundation Of The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US11253538B2 (en) 2015-03-27 2022-02-22 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Similar Documents

Publication Publication Date Title
US3622677A (en) Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4072535A (en) Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3490742A (en) Compressed tablets
US4551177A (en) Compressible starches as binders for tablets or capsules
CA2260637C (en) Free-flowable, directly compressible starch as binder, distinegrant and filler for compression tablets and hard gelatine capsules
US3873694A (en) Direct compression tabletting composition and pharmaceutical tablets produced therefrom
US5169639A (en) Controlled release verapamil tablets
EP1152026B1 (en) Polysaccharide material for direct compression
JPS5818322A (en) Tablet decomposing agent and manufacture
JPH04501713A (en) Long-release excipients that can be directly compressed
MXPA02007458A (en) Continuous method for preparing pharmaceutical granules.
JP2023501107A (en) Use of sodium starch octenyl succinate as a binder in continuous wet granulation
WO1981002521A1 (en) Pharmaceutical vehicle composition and process of producing same
JP4306965B2 (en) Bulking and decomposing composition, method for achieving it and use thereof
JP3253074B2 (en) Method for producing tablets of cefarosporanic acid derivative by direct compression
JP2001114703A (en) Solid medicine and method for producing the same
JP2001039894A (en) Binder for compression tablet and direct compression starch as an enhancer for vehicle in the case where it is used as a disintegrator
Okhamafe et al. Direct Compression Studies on Low-Cost Cellulose derived from Maize Cob.
JP4774739B2 (en) Kampo extract-containing tablet composition and method for producing the same
JP2007332074A (en) Tablet quickly disintegrable in oral cavity and method for producing the same
US20010003619A1 (en) Diluent and desintegrating composition, a process for the preparation thereof and the use thereof
DE1767774C2 (en) Use of a compressed starch powder for direct compression into tablets
JPH0818801B2 (en) Granular tricalcium phosphate composition suitable for direct compression tablet formation
JP2004137230A (en) Solid agent
JPS6328414B2 (en)

Legal Events

Date Code Title Description
AS Assignment

Owner name: STALEY CONTINENTAL, INC., ROLLING MEADOWS, ILLINOI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. EFFECTIVE DEC. 30, 1987.;ASSIGNOR:A.E. STALEY MANUFACTURING COMPANY, A DE CORP.;REEL/FRAME:004935/0533

Effective date: 19871229